Another breakthrough occurred in 1996 with the first generation of a segmented negative-sense RNA virus from cloned cDNAs (Bridgen & Elliott, 1996). Following the approach outlined by Schnell et al. (1994), Bridgen & Elliott (1996) created Bunyamwera virus (family Bunyaviridae), thus demonstrating the feasibility of artificially producing more than one vRNA.

The generation of influenza virus is far more complex than that of nonsegmented negative-sense RNA viruses, as it requires eight vRNAs as well as four proteins encoding the three polymerase subunits and NP. Secondly, influenza virus replicates in the nucleus of infected cells, so that the vRNAs and proteins have to be delivered to this cellular compartment. A solution was provided by Hobom and colleagues (Zobel et al., 1993; Neumann et al., 1994), who established the RNA polymerase I system for the intracellular synthesis of influenza vRNAs. RNA polymerase I, a nucleolar enzyme, synthesizes ribosomal RNA, which, like influenza virus RNA, does not contain 5´ cap or 3´ poly(A) structures. Hence, RNA polymerase I transcription of a cDNA construct containing an influenza viral cDNA, flanked by RNA polymerase I promoter and terminator sequences, results in influenza vRNA synthesis. This system enabled the generation of influenza virus from plasmids in 1999 (Neumann et al., 1999; Fodor et al., 1999; reviewed by Pekosz et al., 1999; Neumann & Kawaoka, 2001) (Fig. 2B). By transfecting eukaryotic cells with eight RNA polymerase I plasmids encoding all vRNAs, together with protein expression constructs for the polymerase and NP proteins (yielding a total of 12 plasmids), one can now produce more than 10⁸ infectious viruses per ml of supernatant derived 2 days after transfection. In a modified RNA polymerase I system, both negative-sense vRNA and positive-sense mRNA can be synthesized from the same template, thus reducing the number of plasmids required (i.e. 8 instead of 12) (Hoffmann et al., 2000a, b; Hoffmann & Webster, 2000).

Thogoto virus, a second member of the family Orthomyxoviridae, was recently generated from plasmids (Wagner et al., 2001). The genome of this tick-transmitted orthomyxovirus consists of six segments of negative-sense RNA. The RNA polymerase I system allowed the synthesis of all six vRNAs, while the proteins required for transcription and replication were expressed with the VV T7 RNA polymerase system.

The genes of nonsegmented negative-sense RNA viruses are separated by regulatory regions comprising a gene end signal (i.e. transcription stop and polyadenylation), an intergenic region and a gene start signal (i.e. transcription start signal) (Fig. 3). These signals are both sufficient and necessary for gene transcription (Kuo et al., 1996b; Schnell et al., 1996b). The gene transcription units are flanked by so-called leader and trailer regions, which contain the viral promoters for replication and transcription.

Fig. 3. Genome organization of nonsegmented negative-sense RNA viruses, as exemplified by VSV. The coding regions for the nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and polymerase protein (L) are separated by regulatory sequences that contain a transcription stop (gene end) signal, a polyadenylation signal, a nontranscribed intergenic region and a transcription start (gene start) signal. Transcription units are flanked by a leader (Le) and trailer (Tr) region that contain the genomic and antigenomic viral promoters, respectively.

The genomic promoter localizes to the 3´ end of the negative-sense vRNA and hence serves as a promoter for both replication and transcription. Distinct elements have been identified in the genomic promoter that are required for transcription but not for replication, or vice versa (Li & Pattnaik, 1999; Whelan & Wertz, 1999; Peeples & Collins, 2000). In contrast, the antigenomic promoter that localizes to the 3´ end of the positive-sense antigenome functions in replication only.

'Rule of six'

Efficient replication for most paramyxoviruses was observed only when the total number of nucleotides was divisible by six (dubbed the 'rule of six') (reviewed by Kolakofsky et al., 1998). The nucleoprotein interacts with exactly 6 nt, and the rule of six seems to depend on the recognition of nucleotides positioned in the proper N-phase context (Vulliemoz & Roux, 2001). Extensive mutagenesis revealed that the rule of six seems to follow taxonomic grouping, being apparently specific to the rubula- (Murphy & Parks, 1997; He & Lamb, 1999; Peeters et al., 2000; Kawano et al., 2001), respiro- (Calain & Roux, 1993, 1995; Harty & Palese, 1995; Hausmann et al., 1996; Durbin et al., 1997b) and morbillivirus (Radecke et al., 1995; Sidhu et al., 1995) genera of the family Paramyxoviridae, although with different stringency. The rule of six is not followed by RSV (Samal & Collins, 1996) nor does it apply to VSV (Pattnaik et al., 1995).

Each RNA segment of the segmented negative-sense RNA viruses constitutes a separate transcription unit. The 5´ 13-terminal and the 3´ 12-terminal nucleotides are highly conserved among the eight viral segments of influenza A viruses and form the basic promoter for transcription and replication (Parvin et al., 1989; Yamanaka et al., 1991; Li & Palese, 1992; Seong & Brownlee, 1992a, b; Piccone et al., 1993). Extensive mutational analyses revealed the contributions of individual nucleotides to in vitro and in vivo promoter activity (Li & Palese, 1992; Piccone et al., 1993; Fodor et al., 1994, 1995; Neumann et al., 1994; Neumann & Hobom, 1995; Pritlove et al., 1995; Flick et al., 1996; Kim et al., 1997). In contrast to the promoter elements of nonsegmented negative-sense RNA viruses, which consist of specific sequence elements at the 3´ ends of the vRNA or cRNA, the genomic and antigenomic promoters of influenza viruses are composed of both the 5´ and the 3´ ends of the vRNA or complementary RNA (cRNA), respectively (Fodor et al., 1993, 1994; Tiley et al., 1994; Neumann & Hobom, 1995; Pritlove et al., 1995). The influenza viral promoters can be divided into two elements: a terminal element (nt 1–9 at the 3´ and 5´ ends of the vRNA or cRNA) and a distal element (nt 10–15 and 11–16 at the 3´ and 5´ ends of the vRNA), which are connected by a flexible joint formed by an unpaired nucleotide (Fodor et al., 1995; Neumann & Hobom, 1995; Flick et al., 1996). Within the terminal element, the nature of the nucleotide sequence is critical, whereas in the distal element, base-pairing between the 3´ and 5´ ends of the vRNA or cRNA is crucial (Fodor et al., 1994, 1995; Neumann & Hobom, 1995; Flick et al., 1996; Kim et al., 1997). Three promoter models, the 'panhandle' model (Hsu et al., 1987), the 'fork' model (Fodor et al., 1994, 1995; Kim et al., 1997) and the 'corkscrew' model (Flick et al., 1996; Flick & Hobom, 1999), have been proposed. The panhandle model suggests formation of a partially double-stranded structure in the entire promoter region, while the fork model proposes double-strand formation for the distal promoter element only. Recent data favour the corkscrew model, which predicts base-pairing between nucleotides at the 5´ or 3´ end rather than base-pairing between the 5´ and 3´ end (Flick & Hobom, 1999; Pritlove et al., 1999; Leahy et al., 2001a, b). The influenza B virus promoter has structural features similar to its influenza A virus counterpart (Lee & Seong, 1996).

During transcription, the polymerase complex proceeds until it encounters the polyadenylation signal, which is formed by a uridine stretch located adjacent to the promoter element. At the uridine stretch, the polymerase complex 'stutters', resulting in polyadenylation (Zheng et al., 1999; Poon et al., 2000). Efficient polyadenylation requires that an uninterrupted uridine stretch be located 15–22 nt from the 5´ end of the vRNA (Luo et al., 1991; Li & Palese, 1994).

The terminal promoter elements contain the information sufficient for replication and transcription; however, signals that modulate these processes seem to be located in the noncoding regions that lie between the promoter and the start or stop codon, respectively. Recombinant viruses with deletions, insertions or mutations in these regions have been generated (Garcia-Sastre et al., 1994b; Barclay & Palese, 1995; Bergmann & Muster, 1996; Zheng et al., 1996). Although these viruses were viable, some had altered amounts of vRNA (Bergmann & Muster, 1996; Zheng et al., 1996).

Although the RNA-dependent RNA polymerase L is believed to contain all catalytic activities, phosphoprotein P is essential for vRNA synthesis. Its interaction with the N protein keeps the latter in a soluble form and imparts specificity to the N protein to encapsidate viral, but not cellular, RNAs. Moreover, binding of P to L allows efficient interaction of L with the N–RNA template (Horikami et al., 1992). Both the amino- and the carboxy-terminal domains of P are critical to execute these functions (De et al., 2000). For VSV P, replacement of single amino acids in the carboxy-terminal region resulted in P mutants that were defective in transcription but supported replication, suggesting that the transcriptase and replicase complexes may not be identical (Das et al., 1997, 1999).

Reverse genetics has also allowed researchers to address the biological significance of P protein phosphorylation in the virus life cycle. The hPIV3 P protein is phosphorylated by the cellular protein kinase C isoform (PKC-) and growth of hPIV3 was abrogated in the presence of a PKC- inhibitor (De et al., 1995). The VSV P protein is phosphorylated at several sites in both the amino- and the carboxy-terminal domains. Replacement of the amino-terminal phosphorylation sites affected transcription (Spadafora et al., 1996; Pattnaik et al., 1997), while the carboxy-terminal phosphorylation sites are necessary for optimal replication (Hwang et al., 1999). In contrast, replacement of the SeV P phosphorylation site did not affect virus replication in cell culture nor did it affect virus pathogenicity in mice (Hu et al., 1999).

Matrix proteins constitute the major structural component of the virion shell. Both the VSV and influenza A virus matrix proteins are essential for virion formation and have the ability to induce particle formation (Sakaguchi et al., 1999; Gomez-Puertas et al., 2000; Jayakar et al., 2000; Latham & Galarza, 2001). In contrast, recombinant MV and RV lacking the M gene (M) have been generated (Cathomen et al., 1998a; Spielhofer et al., 1998; Mebatsion et al., 1999). MVM was more efficient in inducing cell fusion than its wild-type counterpart (Cathomen et al., 1998a). Interestingly, MVs isolated from patients with subacute sclerosing panencephalitis are often defective in M gene expression (Baczko et al., 1984).

The SeV M protein is phosphorylated in infected cells but not in mature virions; therefore, M phosphorylation was thought to regulate processes such as virion assembly or budding. However, a recombinant SeV containing a mutation in M that abrogated phosphorylation was indistinguishable from wild-type virus both in vitro and in vivo (Sakaguchi et al., 1997).

The influenza virus M2 protein is expressed from a spliced mRNA encoded by segment 7. It is an integral membrane protein that executes functions early and late in the virus replication cycle. In late endosomes, the M2 ion channel activity allows proton influx into the virions, thus causing a pH shift that leads to the dissociation of the M1 protein from RNP complexes. Late in infection, proton influx through the M2 ion channel raises the pH in the trans-Golgi network, thereby preventing acid-induced conformational changes in intracellularly cleaved haemagglutinin (HA). Reverse genetics experiments indicated that the M2 cytoplasmic tail is critical for virus replication, most likely through its interaction with other viral proteins (Castrucci & Kawaoka, 1995); in contrast, replacement of either the serine residue at position 64 (the primary M2 phosphorylation site) or the conserved cysteine residues did not compromise the recombinant viruses in vitro or in vivo (Castrucci et al., 1997; Thomas et al., 1998).

M2 ion channel activity was long considered essential for virus replication. However, an influenza virus with a deletion in the M2 transmembrane domain was growth-impaired but still replicated in cell culture (Takeda et al., 2002). Another recombinant virus whose M2 transmembrane and cytoplasmic domains were deleted grew in cell culture but not in mice (Watanabe et al., 2001). Thus, M2 ion channel activity is not essential for virus replication in vitro but it is required for in vivo virus replication.

The influenza A virus NS2 protein is translated from a spliced mRNA encoded by segment 8. It contains a classical nuclear export signal (NES) in its amino-terminal region and mediates nuclear export when fused to a reporter construct (O'Neill et al., 1998). Moreover, NS2 interacted with the cellular nuclear export factor CRM1, which mediates export of proteins with classical NESs (Neumann et al., 2000a). In cells infected with virus-like particles (VLPs) that lacked NS2 or encoded an NS2 protein with an altered NES, viral RNP complexes were retained in the nucleus, thus supporting the role of NS2 as the virus nuclear export factor of viral RNP complexes (Neumann et al., 2000a).

Rhabdoviruses possess a single glycoprotein (G), which is involved in cell attachment and pH-dependent fusion of the viral and cellular membranes. For orthomyxoviruses, the HA protein binds to cellular receptors and mediates the pH-dependent fusion event, while the sialidase activity of the neuraminidase (NA) protein is required to prevent self-aggregation and to prevent viruses from rebinding to cells from which they were released. In contrast to orthomyxoviruses, different proteins encode the attachment and fusion activities for paramyxoviruses. The G (rhabdo- and pneumoviruses), H (morbilliviruses) or HN (respiro- and rubulaviruses) glycoprotein brings about binding to cellular receptors. The fusion (F) protein is involved in the fusion of the viral membrane with the endosomal or plasma membrane, resulting in the release of RNP complexes into the cytoplasm of infected cells. However, for most paramyxoviruses, coexpression of both F and HN is required for fusion activity, indicating a fusion-promoting activity of the HN protein.

Deletion of glycoproteins

A human RSV (hRSV) strain passaged at progressively lower temperatures contains a deletion of the G gene (as well as of the SH gene), demonstrating that these proteins are not essential for virus replication (Karron et al., 1997a); however, a recombinant hRSV lacking G was attenuated in its replication (Techaarpornkul et al., 2001). Similarly, reverse genetics allowed the generation of bovine RSV (bRSV) that lacked the G and/or SH genes (Karger et al., 2001). The artificially generated viruses did not display an altered morphology and grew to titres similar to wild-type virus in cell culture (Karger et al., 2001). Thus, for hRSV and bRSV, the F protein seems to be able to function as an attachment protein, in addition to its critical role in cell fusion (Kahn et al., 1999); however, the G protein is needed for efficient growth of hRSV in mice (Teng et al., 2001).

Proteolytic cleavage of viral glycoproteins determines pathogenicity

Proteolytic cleavage of the viral fusion protein is one of the key factors determining virus pathogenicity. Many of the fusion proteins are synthesized as inactive precursor proteins that are cleaved by host cell proteases to generate two disulfide-linked subunits. It is this activated form that initiates the fusion of the viral and cellular membranes. In avian influenza virus and NDV, fusion proteins (HA for the former virus) possess multiple basic amino acids at their cleavage site that are recognized by ubiquitous cellular proteases, such as furin (Stieneke-Grober et al., 1992). In contrast, the fusion proteins of avirulent viruses contain single basic residues at this site that are not recognized by the ubiquitous proteases, resulting in local infections. For avian influenza A viruses, researchers established a direct link between HA cleavability and virus pathogenicity and demonstrated that two features were critical for HA cleavage: the length and composition of the basic amino acid stretch as well as the presence or absence of a nearby carbohydrate side chain (Kawaoka & Webster, 1988, 1989; Horimoto & Kawaoka, 1994; Klenk & Garten, 1994). The importance of multiple basic amino acids at the F cleavage site has also been demonstrated for NDV (Peeters et al., 1999). For MV, alteration of the multibasic furin cleavage site of the F protein resulted in recombinant virus that did not induce neural disease, in contrast to wild-type virus (Maisner et al., 2000). Reverse genetics also allowed researchers to replace the multibasic furin-recognition motif of the Ebola virus GP protein with nonbasic amino acids. Interestingly, the recovered virus grew to titres similar to wild-type virus in cell culture (Neumann et al., 2002). Hence, furin-mediated cleavage of the Ebola virus GP protein is not critical for virus replication in cell culture; however, it may be required for virus propagation in animals.

Cross et al. (2001) determined the significance of the large hydrophobic amino acids of the influenza A virus fusion peptide, which become exposed after HA cleavage by host cell proteases. Replacement of hydrophobic amino acids with alanine but not with glycine yielded viruses capable of replication. Moreover, cell culture propagation of viruses containing alanine substitutions in the fusion peptide resulted in pseudoreversion to valine, indicating a preference for hydrophobic amino acids with a large side chain in this region (Cross et al., 2001).

Viral glycoproteins determine host cell tropism

Viral glycoproteins are a major factor in determining host cell tropism. To study MV cell tropism, two groups of investigators generated recombinant viruses that contained the H and/or F proteins derived from a lymphotropic wild-type strain (WTF) of MV in the background of the tissue culture-adapted Edmonston vaccine strain (Johnston et al., 1999; Ohgimoto et al., 2001). These studies demonstrated that the WTF H protein can confer the ability to viruses to replicate in secondary lymphoid tissues in cotton rats (Ohgimoto et al., 2001). Furthermore, replacement of the Edmonston strain H gene with that of the wild-type IC-B strain, or vice versa, altered the host cell specificity of the resulting recombinant viruses (Takeuchi et al., 2002).

MV has the potential to cause neurological complications. Substitution of the H gene of the Edmonston B vaccine strain with its counterpart derived from a rodent brain-adapted strain resulted in a neurovirulent, recombinant virus (Duprex et al., 1999). However, infection progressed more slowly in mice infected with recombinant virus compared to the rodent brain-adapted parental strain. Thus, the H protein is an important (although not the only) factor required for neurovirulence.

Two studies addressed the significance of the RV G protein for neurovirulence by introducing G protein derived from neurovirulent strains into the genetic background of less neurotropic strains. While G is the major determinant of neurotropism, other factors seem to contribute to pathogenicity (Morimoto et al., 2000; Ito et al., 2001). Similarly, reciprocal exchange of the canine distemper virus and MV H proteins demonstrated that they are important determinants of the growth characteristics and the cell tropism of the recombinant viruses (von Messling et al., 2001).

Cytoplasmic tails of glycoproteins

The cytoplasmic tails of the attachment and fusion proteins are thought to be critical for virus assembly, most likely through their interaction(s) with internal viral proteins. The influenza A virus HA protein contains conserved, palmytilated cysteine residues in both its cytoplasmic tail and its transmembrane domain. Replacements of these amino acids yielded conflicting results. While two groups reported the generation of influenza viruses lacking the conserved cysteine residues (Jin et al., 1996; Lin et al., 1997), another group failed to generate such mutants (Zurcher et al., 1994). However, these findings may simply reflect the fact that the different HA subtypes used for these studies differ in their abilities to tolerate amino acid replacements. Analysis of recombinant influenza A viruses whose NA tail was replaced with that of influenza B virus, or whose NA and/or HA cytoplasmic tails were deleted, demonstrated that the HA and NA cytoplasmic tails are not absolutely required for virus propagation (Bilsel et al., 1993; Jin et al., 1994, 1997; Garcia-Sastre & Palese, 1995; Mitnaul et al., 1996). However, deletion of the cytoplasmic tails affected the particle shape, reduced the vRNA:protein ratio and attenuated the recombinant viruses in mice, suggesting that the HA and NA cytoplasmic tails affect virion formation and confer a growth advantage to influenza virus (Garcia-Sastre & Palese, 1995; Mitnaul et al., 1996; Jin et al., 1997; Zhang et al., 2000). Similarly, truncation of the cytoplasmic tails of the SV5 HN (Schmitt et al., 1999) or the SeV HN or F proteins (Fouillot-Coriou & Roux, 2000) resulted in recombinant viruses that were impaired in their growth. Recombinant SV5 or MV with alterations in their HN, F and/or H cytoplasmic tails displayed enhanced cell-to-cell fusion (Cathomen et al., 1998b; Schmitt et al., 1999). In addition, basolateral targeting signals have been identified in the cytoplasmic tails of the MV H and F proteins (Moll et al., 2001). For VSV, replacement of the transmembrane and cytoplasmic domains of G with those of human CD4 protein did not affect virion budding (Schnell et al., 1998). Further analysis demonstrated that a short cytoplasmic tail without specific sequence requirements is sufficient to promote efficient budding (Schnell et al., 1998). In addition, a short region in the extracellular stem of G was identified that confers efficient virus assembly (Robison & Whitt, 2000).

Influenza A virus NA protein

The influenza A virus NA protein is composed of a stalk of variable length and amino acid composition that connects the transmembrane domain with the globular head, which contains the enzymatic centre. Recombinant viruses with altered stalks demonstrated that viruses with longer stalks replicated to higher titres in eggs (Castrucci et al., 1992, 1994; Castrucci & Kawaoka, 1993; Luo et al., 1993). Stalk-less viruses were not restricted in their growth in tissue culture but failed to grow in eggs and displayed attenuated phenotypes in mice (Castrucci & Kawaoka, 1993). These findings indicate that the NA stalk is not essential for virus replication but modulates the host range, probably by affecting the enzymatic activity of NA.

The NA protein of the neurovirulent influenza A/WSN/33 virus strain differs from all other influenza A virus NAs by virtue of the lack of a glycosylation site at amino acid position 130. To assess the contribution of this glycosylation site for neurovirulence, Li et al. (1993c) generated a recombinant virus containing the conserved glycosylation site. The recombinant virus, unlike its parent, did not replicate in mouse brain, demonstrating that this NA glycosylation site is critical for neurovirulence. Further studies demonstrated that influenza A/WSN/33 virus NA binds plasminogen, which, after being activated to plasmin, cleaves HA (Goto & Kawaoka, 1998). In vitro and in vivo studies revealed that two NA structural features, a carboxy-terminal lysine residue and the lack of the glycosylation site at position 130, were critical for plasminogen binding (Goto & Kawaoka, 1998; Goto et al., 2001). Recombinant viruses in which either one of these features was altered did not replicate in the brain of infected mice, in contrast to wild-type influenza A/WSN/33 virus (Goto et al., 2001).

Ebola virus glycoprotein GP

Expression of the complete, membrane-anchored form of the Ebola virus glycoprotein is achieved through editing of its mRNA, while the unedited mRNA is translated to the secreted glycoprotein (sGP). About 80 % of the GP mRNAs remain unedited, resulting in high amounts of sGP in patient sera (Volchkov et al., 1995; Sanchez et al., 1996). In contrast, the closely related Marburg virus translates its GP from an unedited mRNA and does not express sGP. To address the role of transcriptional editing and sGP synthesis in Ebola virus replication, Volchkov et al. (2001) generated a virus that expressed GP from an unedited mRNA. The mutant virus expressed higher levels of GP and was more cytotoxic than its wild-type counterpart. This finding suggested that transcriptional editing might control the expression levels of GP and hence the cytotoxic effects of this protein.

Accessory proteins are not essential for basic levels of virus replication and/or transcription but regulate or modulate a variety of steps in the virus life cycle. For VSV and members of the Paramyxovirinae subfamily, accessory proteins are encoded by the P gene and expressed through RNA editing and/or they are expressed from a second reading frame overlapping the P gene. In contrast, accessory proteins of pneumoviruses are expressed from separate, additional transcription units, involving the use of overlapping reading frames.

Influenza A virus NS1 protein

Among negative-sense RNA viruses, the NS1 protein was the first protein shown to counteract the cellular interferon (IFN) response (reviewed by Garcia-Sastre, 2001). In 1998, Garcia-Sastre et al. (1998) generated a NS1 influenza A virus that was restricted in its replication in MDCK cells and mice (hence, in systems with a functional IFN response). In contrast, NS1 influenza A virus replicated to titres comparable to wild-type virus in IFN-compromised systems, such as Vero cells or STAT-1^–/– mice (Garcia-Sastre et al., 1998; Talon et al., 2000b). NS1 interferes with several cellular pathways to combat the antiviral IFN response. Double-stranded RNA-activated protein kinase (PKR) indirectly stimulates type I IFN, thus playing a critical role in antiviral responses. NS1 binds to RNA (Yoshida et al., 1981), thereby suppressing PKR (Hatada et al., 1999; Bergmann et al., 2000). In line with these findings, NS1 influenza A virus, but not wild-type virus, stimulated the expression of a reporter gene under the control of an IFN-responsive promoter (Garcia-Sastre et al., 1998). Moreover, NS1 influenza A virus activated NF-B (Wang et al., 2000), which transactivates IFN--regulated promoters and IFN regulatory factor 3 (Talon et al., 2000a), which forms a transcription complex with signal transducer and transcriptional activator-1 (STAT-1) and STAT-2.

In a study to assess the contribution of NS1 to the extreme pathogenicity of the 'Spanish Flu' virus, which killed 20–40 million people in 1918 and 1919, recombinant viruses were generated that contained the NS1 or both the NS1 and the NS2 encoding regions of the Spanish Flu virus in an influenza A/WSN/33 virus genetic background (Basler et al., 2001). The recombinant viruses did not kill mice, in contrast to the parental influenza A/WSN/33 virus, and the results were considered inconclusive because of gene constellation effects.

C proteins

C proteins (reviewed by Nagai, 1999; Nagai & Kato, 1999) are expressed by VSV, morbilli- and respiroviruses from a second reading frame that overlaps the 5´ region of the P gene in the +1 open reading frame (ORF). Morbilliviruses and hPIV3 encode one C protein. For VSV and SeV, ribosomal choice results in the use of different initiation codons (all in the same reading frame), yielding a nested set of two C proteins (designated C' and C) for VSV or a nested set of four proteins (C´, C, Y1 and Y2) for SeV (Latorre et al., 1998b). C proteins share a common carboxy-terminal region but differ in their amino termini.

The relative importance of C proteins for the virus life cycle differs among rhabdoviruses and paramyxoviruses. VSV defective in C protein expression is indistinguishable from wild-type virus in cell culture (Kretzschmar et al., 1996), while alteration of the C proteins of hPIV3 (Durbin et al., 1999) and RPV (Baron & Barrett, 2000) restricted virus replication in cell culture and/or experimental animals. The growth characteristics of MVC depended on the cell line tested (Radecke & Billeter, 1996; Escoffier et al., 1999) and MV deficient in C protein expression was attenuated in mice (Patterson et al., 2000). For SeV, C´ protein-deficient virus was as virulent as wild-type virus in mice, while C protein-deficient virus was highly attenuated in these animals (Latorre et al., 1998a); this phenotype was attributed to a single amino acid substitution in the SeV C protein (Garcin et al., 1997). Recombinant SeV deficient in the expression of all four C proteins was severely attenuated and grew to titres of 4 log units lower than those observed for the wild-type counterpart (Kurotani et al., 1998). Most importantly, SeV employs all four C proteins to diminish the induction of IFN-stimulated gene expression (Didcock et al., 1999a; Garcin et al., 1999, 2000; Kato et al., 2001), as demonstrated by the experimental requirement to ablate the entire complement of C proteins to fully suppress IFN--stimulated gene expression (Gotoh et al., 1999). While all four C proteins interfered with STAT-1 phosphorylation, only C and C´ proteins induced its instability (Garcin et al., 2001).

The various C proteins have both positive and negative effects on virus replication and seem to execute their function(s) in a highly coordinated manner (Cadd et al., 1996; Garcin et al., 1997; Tapparel et al., 1997; Kurotani et al., 1998; Latorre et al., 1998a; Baron & Barrett, 2000; Kato et al., 2001; Reutter et al., 2001). Moreover, C proteins may execute functions in assembly, since a recombinant SeV that did not express any of its C proteins differed in size and shape from wild-type virus (Hasan et al., 2000). Thus, although not absolutely required for virus amplification, the C proteins affect several steps in the virus life cycle.

V proteins

With the exception of hPIV1, all morbilli-, rubula- and respiroviruses contain a V gene (reviewed by Nagai, 1999; Nagai & Kato, 1999). For SeV, NDV and morbilliviruses, V protein expression relies on the insertion of one or two nontemplated G residues into the P gene through RNA editing. In contrast, the rubulavirus V protein is translated from an unedited mRNA. All V proteins share their amino-terminal region with the respective P protein but have a unique carboxy terminus. Suppression of V protein expression has only minor effects on RPV replication (Baron & Barrett, 2000), while NDVV replicated to lower titres in cell culture and was severely attenuated in chickens' eggs (Mebatsion et al., 2001). Recombinant SeV or MV deficient in V protein expression were not restricted in replication in cell culture (Delenda et al., 1997; Schneider et al., 1997a; Escoffier et al., 1999; Patterson et al., 2000) but were attenuated in animals (Kato et al., 1997a, b; Delenda et al., 1998; Tober et al., 1998; Valsamakis et al., 1998; Patterson et al., 2000). hPIV2V did not grow in CV-1 cells but replicated in Vero cells (Kawano et al., 2001), suggesting a role of the V protein in interplay with the cellular immune response.

The carboxy-terminal domain of V protein (which is not shared by the P protein) contains a cysteine-rich, zinc finger-like domain that is critical for pathogenicity (Kato et al., 1997b; Huang et al., 2000). It interacts with the large subunit of the cellular damage-specific DNA-binding protein (UV-DDB), as shown for SV5, hPIV2, MV and mumps virus (Lin et al., 1998). This interaction is likely responsible for the delay in the division cycle of SV5-infected cells; indeed, the cell cycle progressed normally in cells infected with recombinant SV5 expressing a truncated V protein lacking the unique carboxy terminus (Lin & Lamb, 2000). Most importantly, V proteins interfere with the IFN response. The SV5 V protein targets STAT-1 for proteasome-mediated degradation (Didcock et al., 1999b; Young et al., 2000, 2001). Thus, SV5 and SeV (through its C proteins) target STAT-1, thereby blocking both type I and type II IFN signalling. In contrast, the V protein of hPIV2 induces proteolytic degradation of STAT-2, so that type I but not type II IFN signalling is abolished (Parisien et al., 2001).

RSV NS1 and NS2 proteins

The 3´ proximal genes of pneumoviruses (in genome orientation) encode two short, nonstructural proteins (NS1 and NS2) that are missing in other paramyxoviruses. The hRSV NS1 protein was identified as a regulatory protein since it inhibited both transcription and replication in minireplicon systems (Atreya et al., 1998). Deletion of the NS1 gene resulted in virus that was attenuated in chimpanzees (Teng et al., 2000), confirming the role of NS1 in virus growth. Deletion or insertion of a stop codon in the RSV NS2 gene resulted in recombinant viruses that were attenuated in cell culture (Teng & Collins, 1999) and in chimpanzees (Whitehead et al., 1999a). Passage of the NS2 stop mutant in cell culture yielded revertant viruses whose artificial NS2 stop codon had been replaced with a sense codon, thus restoring expression of a (mutant) NS2 protein (Teng & Collins, 1999). This finding demonstrated that, although not essential, NS2 confers a growth advantage to hRSV replication in cell culture. Schlender et al. (2000) generated bRSV mutants that do not express NS1 and/or NS2. These viruses were highly attenuated in MDBK cells but only moderately affected in IFN-deficient Vero cells, suggesting that NS1 and NS2 antagonize the IFN-mediated antiviral response. For bRSV, both the NS1 and NS2 proteins are required to control the IFN-/-mediated cellular response (Schlender et al., 2000). Although hRSV continues to replicate in cells pretreated with type I IFN (Atreya & Kulkarni, 1999), it does not block either type I or type II IFN signalling (Young et al., 2000). These findings suggest that hRSV developed an alternative strategy to counteract the cellular IFN response, one that most likely interferes with events downstream of IFN signalling.

RSV M2 gene

Expression of the hRSV N, P and L proteins, together with a plasmid-encoded minigenome, resulted in premature termination of mRNA synthesis (Collins et al., 1996). Coexpression of low levels of the M2 gene yielded full-length mRNAs and polycistronic read-through transcripts, whereas higher amounts of the M2 gene inhibited replication and transcription (Collins et al., 1996). Similarly, small amounts of the M2 gene enhanced transcription of a bRSV minigenome (Yunus et al., 1998). Further study of the M2 gene, which contains two overlapping ORFs, revealed that M2-1 is required to synthesize full-length mRNAs and read-through transcripts (Collins et al., 1996; Fearns & Collins, 1999) by functioning as an elongation factor and an antitermination factor (Collins et al., 1996; Hardy & Wertz, 1998; Fearns & Collins, 1999; Hardy et al., 1999). In contrast, the M2-2 protein inhibits RNA replication (Collins et al., 1996; Jin et al., 2000a) and may play a role in the switch from transcription to replication (Bermingham & Collins, 1999). Consequently, recombinant RSVs that lost the ability to express M2-2 were restricted in their growth in cell culture and in animal models (Bermingham & Collins, 1999; Jin et al., 2000a; Teng et al., 2000).

SH proteins

The hRSV SH protein is a short transmembrane protein of unknown function. Deletion of SH in a recombinant RSV did not affect RNA replication but slightly increased virus titres in certain cell lines (Bukreyev et al., 1997; Techaarpornkul et al., 2001) and caused moderate attenuation in animal models (Bukreyev et al., 1997; Whitehead et al., 1999a). Deletion of the SV5 SH protein did not significantly alter the growth characteristics of a recombinant virus in cell culture (He et al., 1998). However, SV5SH induced greater DNA fragmentation and higher caspase-2 and caspase-3 activities than did wild-type virus, indicating that the SH protein interferes with apoptosis (He et al., 2001).

In one study, expression of the RSV M2-2, NS1, NS2 and SH proteins was abrogated in various combinations (Jin et al., 2000b). Virus in which all four genes were deleted could not be generated and deletion of the M2-2 gene together with the NS1 gene also proved detrimental to virus replication. However, recombinant viruses, such as RSVSH, NS1 and NS2, were viable, although they were attenuated in cell culture and in cotton rats. Replication of recombinant viruses was more affected in HEp-2 than in Vero cells, suggesting that one or more of the deleted genes encode proteins that counteract the cellular IFN response. Taken together, these findings indicate that although the RSV M2-2, NS1, NS2 and SH proteins are not essential for virus replication, they encode supporting functions required for efficient virus replication.

Negative-sense RNA viruses have several biological features that make them promising candidates as vaccine or targeting vectors. Most importantly, they do not replicate through DNA intermediates, so that integration of their genomes into the host cell genome is a remote possibility. Also, most members of this virus group grow to high titres, accommodate additional genetic material and express the foreign peptides or proteins at high levels. Moreover, strong humoral and cellular immune responses have been observed after immunization with negative-sense RNA virus vectors.

Nonsegmented negative-sense RNA viruses

Initial experiments using reporter proteins demonstrated that nonsegmented negative-sense RNA viruses will accommodate foreign genetic material and stably maintain it during serial passages in cell culture (Bukreyev et al., 1996; Mebatsion et al., 1996; Hasan et al., 1997). However, the insertion of additional genetic material decreased virus yield in cell culture (Bukreyev et al., 1996; Hasan et al., 1997; Sakai et al., 1999; Skiadopoulos et al., 2000) and recombinant viruses were attenuated in animal models (Sakai et al., 1999; Skiadopoulos et al., 2000).

Because of the medical importance of human immunodeficiency virus type 1 (HIV-1), a number of studies explored the generation of recombinant viruses expressing retroviral glycoproteins or their cellular receptors. An initial study demonstrated that the human CD4 protein, which serves as the cellular receptor for HIV-1, was expressed from recombinant VSV together with the VSV G protein (Schnell et al., 1996a). This approach was taken one step further with the generation of RVG pseudotyped by transient expression of a chimeric CD4 RV G protein and CXCR4, or by a recombinant VSVG expressing CD4 and CXCR4 from the viral genome (Mebatsion et al., 1997; Schnell et al., 1997). Both the pseudotyped RV and the recombinant VSV selectively infected cells expressing an X4-specific HIV-1 envelope protein, suggesting that gene delivery vectors that specifically recognize HIV-1-infected cells might be useful tools in targeting and eliminating these cells.

To explore the potential of nonsegmented negative-sense RNA viruses as vaccine vectors, a number of investigators generated recombinant RV or VSV expressing the HIV-1 envelope protein and found that they specifically infected CD4⁺ cells (Mebatsion & Conzelmann, 1996; Johnson et al., 1997; Boritz et al., 1999). After a boost with HIV-1 gp120 protein, mice inoculated with the recombinant RV developed a strong humoral response against the HIV-1 protein (Schnell et al., 2000). Also, a recombinant SeV expressing HIV-1 envelope protein was generated and infected natural HIV-1 host cells, such as human primary blood mononuclear cells, macrophages and established T cell lines (Yu et al., 1997).

The HIV-1 Gag protein is another potential target for cell-mediated host immune defence, leading several research groups to generate viruses that expressed this protein. RV expressing HIV-1 Gag induced a strong cytotoxic T lymphocyte response against this protein in mice. A recombinant VSV expressing both Env and Gag demonstrated that VSV can accommodate up to a 40 % increase in its genome size (Haglund et al., 2000). More importantly, this virus protected rhesus monkeys from challenge with a pathogenic HIV-1 (Rose et al., 2001), thus demonstrating the potential of recombinant VSV as a vaccine vector.

Since the viral glycoproteins are critical in eliciting an antiviral response, viruses were generated with heterologous surface glycoproteins. Glycoproteins can be exchanged between members of the Pneumo- and Respirovirus genera, as demonstrated by bRSV, whose G and F proteins were replaced with the HN and F proteins of bovine PIV3 (bPIV3) (Stope et al., 2001). Recombinant bRSV was also recovered after replacement of the attachment glycoprotein only, while replacement of only the fusion protein abrogated virus generation (Stope et al., 2001). Substitution of the MV H and F genes with the VSV G gene in a MV genetic background generated attenuated virus that protected mice against challenge with wild-type VSV (Spielhofer et al., 1998). Furthermore, recombinant VSV expressing influenza A virus HA or NA proteins (Kretzschmar et al., 1997) protected vaccinated mice from lethal challenge with influenza virus (Roberts et al., 1998, 1999). One of the problems associated with VSV vaccine vectors is the potential for induction of neutralizing-antibodies against the VSV G protein, thus preventing reinfection and boosting with the same vector. One study addressed this problem by generating VSV vaccine vectors that were based on the Indiana serotype but contained the glycoprotein genes of the New Jersey or Chandripura subtypes (Rose et al., 2000). The G protein shuttle vectors did not induce cross-neutralizing antibodies and could therefore be useful tools when boosting of immune responses is desirable.

The immune response to virus infections can be enhanced or modulated by the coexpression of cytokines. This strategy was tested by generating MV expressing IL-12 (Singh & Billeter, 1999) or recombinant RSV expressing IFN- (Bukreyev et al., 1999) or IL-2 (Bukreyev et al., 2000b). While for the former virus expression of IL-12 was demonstrated, the latter two viruses were attenuated, ostensibly due to the antiviral activity of IFN- or IL-2, respectively.

Influenza virus vectors

Influenza A viruses are promising vector candidates (reviewed by Garcia-Sastre, 2000) because of the availability of 15 HA and 9 NA subtypes, as well as numerous antigenic variants, which would allow repeated immunization. Recombinant viruses expressing foreign polypeptides integrated into the NA stalk or the antigenic sites of HA have been generated (Li et al., 1992, 1993a, b; Castrucci et al., 1994; Muster et al., 1994, 1995; Isobe et al., 1995; Murata et al., 1996; Gilleland et al., 1997; Walker et al., 1997). Results demonstrating immune responses against the foreign peptides include expression of the V3 loop of HIV-1 gp120 protein (Li et al., 1993a), expression of an epitope from the HIV-1 gp41 ectodomain (Muster et al., 1994, 1995) and expression of a cytotoxic T lymphocyte-specific epitope of the lymphocytic choriomeningitis virus nucleoprotein (Castrucci et al., 1994).

Several approaches have been explored to express full-length foreign proteins from influenza A virus vectors. Generation of a bicistronic vRNA with an internal ribosomal entry site (IRES) allowed the expression of a foreign protein via the cap-mediated initiation of translation, while the influenza A virus NA was translated by IRES-mediated internal binding of ribosomes (Garcia-Sastre et al., 1994a). Alternatively, the 17 aa self-cleaving 'protease 2A' sequence from foot-and-mouth disease virus can be inserted between a foreign and a viral protein (Percy et al., 1994). The resulting polyprotein is then cleaved to release the foreign and the viral protein; however, recent findings indicate that the protease 2A sequence may function as an IRES instead of a protease (Donnelly et al., 2001).

In contrast to the generation of bicistronic vRNAs or polyproteins, full-length foreign proteins can also be expressed from additional gene segments. Initial experiments with reporter gene constructs demonstrated that additional gene segments were maintained for only about three passages in cell culture (Luytjes et al., 1989). However, a promoter mutant significantly increased the expression of a reporter construct, most likely because of its preferential replication and/or transcription (Neumann & Hobom, 1995). On the strength of this finding, a recombinant influenza A virus was generated that maintained an additional gene segment with the respective promoter mutations for at least 11 passages in cell culture (Zhou et al., 1998).

Gene delivery particles

The reverse genetics systems established for nonsegmented and segmented negative-sense RNA viruses can also be used to generate VLPs for gene delivery purposes. These particles lack one or more viral genes encoding structural proteins; hence, infectious progeny viruses cannot be generated. A SeV genome whose F gene was replaced with that of a reporter gene formed particles only when supplemented with F protein (Li et al., 2000). These particles infected fresh cells, resulting in expression of the reporter gene construct. For influenza virus, VLPs were generated by expressing all viral structural proteins and a virus-like RNA that encodes a reporter protein (Mena et al., 1996; Gomez-Puertas et al., 1999; Neumann et al., 2000b). The potential of influenza VLPs as vaccines was demonstrated by Watanabe et al. (2002), who generated replication-incompetent particles from cloned cDNAs that lacked the entire NS gene or the NS2 encoding region. Vaccination of mice with the latter protected 94 % of mice from challenge with a lethal dose of a homologous influenza virus.

Many negative-sense RNA viruses have medical or economical importance (or both), providing a compelling rationale for the development of vaccines that would effectively combat these pathogens. Reverse genetics has opened the door for the development of live attenuated vaccine viruses by introducing attenuating mutations and/or genome rearrangements (Wertz et al., 1998; Ball et al., 1999; Flanagan et al., 2000, 2001), which should induce both humoral and cellular immunity, thus increasing the likelihood of protection from disease. Such vaccines should be more stable and, thus, safer than conventional live attenuated viruses.

RSV

RSV is the leading cause of viral bronchiolitis and pneumonia in infants and young children worldwide and a protective vaccine is greatly needed (reviewed by Collins et al., 1999). Growth of the wild-type RSV A2 strain at progressively lower temperatures yielded a virus (cpRSV), which was, however, neither significantly cold-adapted nor temperature-sensitive and still caused upper respiratory disease in seronegative children. In comparison with its parent, cpRSV contained five amino acid replacements whose introduction into a wild-type-like RSV background reconstituted the cpRSV phenotype (Whitehead et al., 1998b). This mutant was subjected to chemical mutagenesis, followed by biological selection for temperature-sensitivity, in an effort to increase its attenuation. This approach resulted in the temperature-sensitive (ts) phenotype cpts248 and cpts530 RVSs; further chemical mutagenesis yielded cpts530/1030, cpts530/1009 and cpts248/404 RSVs. Reverse genetics allowed researchers to determine the relative contributions of individual mutations to the ts, attenuated (att) and cold-adapted (ca) phenotypes of RSV (Juhasz et al., 1997, 1999a, b; Whitehead et al., 1998a). Two of these viruses (cpts530/1009 and cpts248/404 RSVs) were tested in infants and children but neither was sufficiently attenuated (Karron et al., 1997b; Wright et al., 2000). Hence, efforts were made to attenuate cpts248/404 RSV even further by deleting the SH gene (Whitehead et al., 1999a). This modification did not produce the desired results in chimpanzees; however, a more attenuated phenotype might only be apparent in humans. Recombinant viruses that contained combinations of mutations derived from different lineages were also generated. Introduction of an attenuating mutation found in RSV cpts530/1030 into the cpts248/404 RSV background yielded a virus that was more temperature-sensitive and attenuated than cpts248/404 (Whitehead et al., 1999b). Alternatively, RSVNS1 or RSVM2-2 might be useful as vaccines, since their replication in the upper respiratory tract of chimpanzees was restricted 10-fold more than that of RSV cpts248/404 (Teng et al., 2000).

bRSV is highly restricted for replication in the respiratory tract of primates and therefore has potential as a RSV vector backbone. Substitution of the bRSV G and F genes with their hRSV counterparts generated a virus that did not confer significant protection against challenge with hRSV in chimpanzees, indicating that it was overattenuated (Buchholz et al., 2000).

RSV exists in two antigenic subgroups, A and B, both of which should be included in a vaccine. In order to develop a vaccine candidate, Whitehead et al. (1999c) introduced the G and F genes of the B1 strain of RSV subtype B into the RSV subtype A cpts248/404 backbone. The resultant recombinant virus proved to be highly attenuated and immunogenic in chimpanzees and protected animals against challenge with subtype B RSV (Whitehead et al., 1999c). Similarly, the subtype B glycoproteins were introduced into the subtype A wild-type RSV genome and, to further attenuate the virus, the M2-2 gene was deleted. The resultant virus was highly attenuated in African green monkeys and induced protection against subtype B RSV challenge (Cheng et al., 2001).

hPIV

hPIV1, -2 and -3 are important causes of viral respiratory disease in infants and young children. Growth of the parental JS strain at progressively lower temperatures yielded a live attenuated hPIV3 candidate vaccine. The resultant virus (termed cp45) is cold-adapted, temperature-sensitive and attenuated for growth in the respiratory tracts of hamsters, rhesus monkeys, chimpanzees and humans. hPIV cp45 differs from the parental JS strain by a total of 20 nt replacements and reverse genetics demonstrated that multiple mutations contributed to each of the ca, ts and att phenotypes (Durbin et al., 1997a; Skiadopoulos et al., 1998, 1999a). To attenuate cp45 hPIV further, Skiadopoulos et al. (1999b) introduced an L gene mutation that specifies the ts and att phenotypes of a live attenuated RSV into the hPIV3 cp45 background, creating a virus that was more temperature-sensitive and attenuated than its parent. In another study, a bivalent vaccine virus was generated that contained the MV H gene integrated into the background of wild-type or attenuated hPIV3 (Durbin et al., 2000). Attenuated hPIV3 expressing the MV H protein not only protected hamsters against challenge with hPIV3 but also elicited high levels of MV-neutralizing antibodies.

Vaccines against PIV1 and -2 are not available and there is a lack of promising live attenuated vaccine candidates. In an attempt to generate a vaccine candidate, the HN and F glycoproteins of a wild-type hPIV3 isolate were replaced with those of hPIV1 (Tao et al., 1998). Next, ts and att mutations identified in the L gene of hPIV3 cp45 were introduced (Tao et al., 1999). Alternatively, the HN and F glycoprotein genes of hPIV1 were directly integrated into the genetic backbone of hPIV3 cp45 (Skiadopoulos et al., 1999c). A similar approach was pursued to generate an hPIV2 vaccine candidate; however, hPIV3/hPIV2 chimeric viruses were viable only when the HN and F cytoplasmic tails were derived from hPIV3 (Tao et al., 2000b). Chimeric hPIV3/hPIV1 and hPIV3/hPIV2 viruses were attenuated in replication in hamsters and provided protection against challenge with homologous wild-type virus (Skiadopoulos et al., 1999c; Tao et al., 1999, 2000a, b).

A different approach explored the use of bPIV3/hPIV3 chimeric viruses as live attenuated vaccines. Introduction of the hPIV3 HN and F genes into a bPIV3 background created a chimeric virus that was attenuated and protected hamsters from challenge with hPIV3 (Haller et al., 2000). Furthermore, a bivalent vaccine virus was generated that contained the hPIV3 F and HN genes and the RSV G or F gene in an otherwise bPIV3 background (Schmidt et al., 2001). The resultant virus induced protection against both hPIV3 and RSV.

Introduction of the bPIV3 N gene into an hPIV3 genetic background identified the N protein as the determinant for host range restriction of bPIV3 in primates (Bailly et al., 2000). The addition of the MV HA gene to this genetic background yielded a bivalent virus that elicited immune response to both MV and hPIV3 (Skiadopoulos et al., 2001).

Influenza viruses

Growth of influenza A and B viruses at progressively lower temperatures yielded cold-adapted, temperature-sensitive, attenuated master strains with mutations in some of the genes encoding internal proteins. Coinfection of cells with a circulating wild-type virus then allows, through natural reassortment, the selection of viruses that contain the genes encoding the internal proteins from the attenuated master virus, while the genes encoding the surface glycoproteins are derived from the circulating wild-type virus. Currently, live attenuated influenza A and B viruses are in clinical trials (Belshe et al., 1998; Maassab & Bryant, 1999; Boyce & Poland, 2000) but these viruses contain only a limited number of amino acid replacements (Cox et al., 1986, 1988; Herlocher et al., 1996), leaving the risk of reversion to a wild-type sequence. The systems established recently for the generation of influenza viruses from cloned cDNAs could therefore be used to design 'master strains' with multiple attenuating mutations in all viral proteins. Examples include temperature-sensitive mutations in the polymerase PB2 protein (Subbarao et al., 1995; Parkin et al., 1996, 1997) or deletion of the NS1 gene, which resulted in highly attenuated viruses that protected mice against wild-type infection (Talon et al., 2000b).

RPV

RPV causes severe disease in cattle, leading to appreciable economic losses. An effective live attenuated vaccine is available that provides lifelong protection, but only one RPV serotype exists, so that vaccinated animals cannot be distinguished from those that developed immunity due to a natural infection. To overcome this problem, Walsh et al. (2000a, b) generated recombinant RPV that expressed genetic markers, such as green fluorescent protein (GFP) or the influenza virus HA. Cattle immunized with the recombinant viruses expressed anti-GFP or anti-HA antibodies and developed protective immunity against RPV (Walsh et al., 2000b).

Peste-des-petits-ruminant virus (PPRV)

PPRV causes an infection in sheep and goats that clinically resembles RPV infections. Both viruses are members of the Morbillivirus genus and their genetic relationship allowed the generation of a recombinant RPV that expressed the PPRV F and H proteins (Das et al., 2000). In contrast, no virus was recovered when only one glycoprotein was replaced. Further studies demonstrated that the RPV/PPRV chimeric virus was attenuated in cell culture and protected goats against infection with wild-type PPRV (Das et al., 2000).

NDV

The severe effects of NDV cause major economic losses within the poultry industry. As with RPV, a live attenuated vaccine is available to combat NDV but vaccinated animals cannot be distinguished from those infected by wild-type virus. Thus, a recombinant virus was generated that expressed the NDV F protein and a chimeric HN protein whose immunogenic globular head was replaced with that of avian paramyxovirus type 4 (APMV4) (Peeters et al., 2001). Neutralizing antibodies are developed against the NDV F protein, while the antibodies developed against the APMV4 HN protein allow a distinction from wild-type NDV isolates (Peeters et al., 2001).

Less than a decade ago, it was not possible to generate negative-sense RNA viruses. Now, through a series of major scientific advances, investigators have the tools to genetically engineer members of the Rhabdo-, Paramyxo-, Filo-, Bunya- and Orthomyxoviridae families, while a minireplicon system is available for a member of the Arenaviridae (Lee et al., 2000); no such system has been reported for Borna virus. The insights afforded by these advances not only have the potential to increase understanding of virus life cycles but should also help to clarify the mechanisms by which these viruses cause disease. As exemplified by studies of Hatta et al. (2001), reverse genetics can be used to generate single-gene reassortants between highly virulent and avirulent H5N1 influenza viruses, e.g. those infecting humans in Hong Kong in 1997. Two single amino acid substitutions in the PB2 and HA proteins were found to determine the pathogenic potential of these influenza viruses (Hatta et al., 2001). The ability to decipher complex mechanisms of virus pathogenicity will no doubt increase our preparedness for future outbreaks. Finally, reverse genetics will allow researchers to design vectors for therapeutic gene delivery and to produce live attenuated vaccines against the many diseases caused by negative-sense RNA viruses.

We thank John Gilbert for editing the manuscript and Yuko Kawaoka for illustrations. We also thank the members of our laboratories who contributed to the original work presented in this review. Support for this work came from grants-in-aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology, CREST (Japan Science and Technology Corporation), and US NIAID Public Health Service research grants.

Atreya, P. L. & Kulkarni, S. (1999). Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261, 227–241.

Atreya, P. L., Peeples, M. E. & Collins, P. L. (1998). The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. Journal of Virology 72, 1452–1461.

Baczko, K., Cater, M. J., Billeter, M. & ter Meulen, V. (1984). Measles virus gene expression in subacute sclerosing panencephalitis. Virus Research 1, 585–595.

Bailly, J. E., McAuliffe, J. M., Durbin, A. P., Elkins, W. R., Collins, P. L. & Murphy, B. R. (2000). A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. Journal of Virology 74, 3188–3195.

Ball, L. A., Pringle, C. R., Flanagan, B., Perepelitsa, V. P. & Wertz, G. W. (1999). Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. Journal of Virology 73, 4705–4712.

Barclay, W. S. & Palese, P. (1995). Influenza B viruses with site-specific mutations introduced into the HA gene. Journal of Virology 69, 1275–1279.

Baron, M. D. & Barrett, T. (1997). Rescue of rinderpest virus from cloned cDNA. Journal of Virology 71, 1265–1271.

Baron, M. D. & Barrett, T. (2000). Rinderpest viruses lacking the C and V proteins show specific defects in growth and transcription of viral RNAs. Journal of Virology 74, 2603–2611.

Barr, J. N. & Wertz, G. W. (2001). Polymerase slippage at vesicular stomatitis virus gene junctions to generate poly(A) is regulated by the upstream 3´-AUAC-5´ tetranucleotide: implications for the mechanism of transcription termination. Journal of Virology 75, 6901–6913.

Barr, J. N., Whelan, S. P. & Wertz, G. W. (1997a). Cis-acting signals involved in termination of vesicular stomatitis virus mRNA synthesis include the conserved AUAC and the U7 signal for polyadenylation. Journal of Virology 71, 8718–8725.

Barr, J. N., Whelan, S. P. & Wertz, G. W. (1997b). Role of the intergenic dinucleotide in vesicular stomatitis virus RNA transcription. Journal of Virology 71, 1794–1801.

Basler, C. F., Reid, A. H., Dybing, J. K., Janczewski, T. A., Fanning, T. G., Zheng, H., Salvatore, M., Perdue, M. L., Swayne, D. E., Garcia-Sastre, A., Palese, P. & Taubenberger, J. K. (2001). From the cover: sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proceedings of the National Academy of Sciences, USA 98, 2746–2751.

Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K., Iacuzio, D. & Wolff, M. (1998). The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. New England Journal of Medicine 338, 1405–1412.

Bergmann, M. & Muster, T. (1996). Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation. Virus Research 44, 23–31.

Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K., Palese, P. & Muster, T. (2000). Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. Journal of Virology 74, 6203–6206.

Bermingham, A. & Collins, P. L. (1999). The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proceedings of the National Academy of Sciences, USA 96, 11259–11264.

Bilsel, P., Castrucci, M. R. & Kawaoka, Y. (1993). Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions. Journal of Virology 67, 6762–6767.

Boritz, E., Gerlach, J., Johnson, J. E. & Rose, J. K. (1999). Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. Journal of Virology 73, 6937–6945.

Boyce, T. G. & Poland, G. A. (2000). Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomedicine & Pharmacotherapy 54, 210–218.

Bridgen, A. & Elliott, R. M. (1996). Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proceedings of the National Academy of Sciences, USA 93, 15400–15404.

Buchholz, U. J., Finke, S. & Conzelmann, K. K. (1999). Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. Journal of Virology 73, 251–259.

Buchholz, U. J., Granzow, H., Schuldt, K., Whitehead, S. S., Murphy, B. R. & Collins, P. L. (2000). Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. Journal of Virology 74, 1187–1199.

Buchmeier, M. J., Bowen, M. D. & Peters, C. J. (2001). Arenaviridae: The viruses and their replication. In Fields Virology, 4th edn, pp. 1635–1668. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Bukreyev, A., Camargo, E. & Collins, P. L. (1996). Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. Journal of Virology 70, 6634–6641.

Bukreyev, A., Whitehead, S. S., Murphy, B. R. & Collins, P. L. (1997). Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. Journal of Virology 71, 8973–8982.

Bukreyev, A., Whitehead, S. S., Bukreyeva, N., Murphy, B. R. & Collins, P. L. (1999). Interferon-g expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proceedings of the National Academy of Sciences, USA 96, 2367–2372.

Bukreyev, A., Murphy, B. R. & Collins, P. L. (2000a). Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo. Journal of Virology 74, 11017–11026.

Bukreyev, A., Whitehead, S. S., Prussin, C., Murphy, B. R. & Collins, P. L. (2000b). Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines. Journal of Virology 74, 7151–7157.

Cadd, T., Garcin, D., Tapparel, C., Itoh, M., Homma, M., Roux, L., Curran, J. & Kolakofsky, D. (1996). The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in a promoter-specific fashion. Journal of Virology 70, 5067–5074.

Calain, P. & Roux, L. (1993). The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. Journal of Virology 67, 4822–4830.

Calain, P. & Roux, L. (1995). Functional characterization of the genomic and antigenomic promoters of Sendai virus. Virology 212, 163–173.

Calain, P., Curran, J., Kolakofsky, D. & Roux, L. (1992). Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA. Virology 191, 62–71.

Castrucci, M. R. & Kawaoka, Y. (1993). Biologic importance of neuraminidase stalk length in influenza A virus. Journal of Virology 67, 759–764.

Castrucci, M. R. & Kawaoka, Y. (1995). Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein. Journal of Virology 69, 2725–2728.

Castrucci, M. R., Bilsel, P. & Kawaoka, Y. (1992). Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase. Journal of Virology 66, 4647–4653.

Castrucci, M. R., Hou, S., Doherty, P. C. & Kawaoka, Y. (1994). Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. Journal of Virology 68, 3486–3490.

Castrucci, M. R., Hughes, M., Calzoletti, L., Donatelli, I., Wells, K., Takada, A. & Kawaoka, Y. (1997). The cysteine residues of the M2 protein are not required for influenza A virus replication. Virology 238, 128–134.

Cathomen, T., Mrkic, B., Spehner, D., Drillien, R., Naef, R., Pavlovic, J., Aguzzi, A., Billeter, M. A. & Cattaneo, R. (1998a). A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO Journal 17, 3899–3908.

Cathomen, T., Naim, H. Y. & Cattaneo, R. (1998b). Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. Journal of Virology 72, 1224–1234.

Cheng, X., Zhou, H., Tang, R. S., Munoz, M. G. & Jin, H. (2001). Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys. Virology 283, 59–68.

Clarke, D. K., Sidhu, M. S., Johnson, J. E. & Udem, S. A. (2000). Rescue of mumps virus from cDNA. Journal of Virology 74, 4831–4838.

Collins, P. L., Mink, M. A. & Stec, D. S. (1991). Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proceedings of the National Academy of Sciences, USA 88, 9663–9667.

Collins, P. L., Hill, M. G., Camargo, E., Grosfeld, H., Chanock, R. M. & Murphy, B. R. (1995). Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5´ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proceedings of the National Academy of Sciences, USA 92, 11563–11567.

Collins, P. L., Hill, M. G., Cristina, J. & Grosfeld, H. (1996). Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proceedings of the National Academy of Sciences, USA 93, 81–85.

Collins, P. L., Whitehead, S. S., Bukreyev, A., Fearns, R., Teng, M. N., Juhasz, K., Chanock, R. M. & Murphy, B. R. (1999). Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Advances in Virus Research 54, 423–451.

Conzelmann, K. K. (1996). Genetic manipulation of non-segmented negative-strand RNA viruses. Journal of General Virology 77, 381–389.

Conzelmann, K. K. (1998). Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annual Review of Genetics 32, 123–162.

Conzelmann, K. K. & Meyers, G. (1996). Genetic engineering of animal RNA viruses. Trends in Microbiology 4, 386–393.

Conzelmann, K. K., Cox, J. H. & Thiel, H. J. (1991). An L (polymerase)-deficient rabies virus defective interfering particle RNA is replicated and transcribed by heterologous helper virus L proteins. Virology 184, 655–663.

Cox, N. J., Kitame, F., Klimov, A., Koennecke, I. & Kendal, A. P. (1986). Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza virus: detection of mutations in all genes of the A/Ann Arbor/6/60 (H2N2) mutant vaccine donor strain. Microbial Pathogenesis 1, 387–397.

Cox, N. J., Kitame, F., Kendal, A. P., Maassab, H. F. & Naeve, C. (1988). Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 167, 554–567.

Cross, K. J., Wharton, S. A., Skehel, J. J., Wiley, D. C. & Steinhauer, D. A. (2001). Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics. EMBO Journal 20, 4432–4442.

Curran, J. & Kolakofsky, D. (1999). Replication of paramyxoviruses. Advances in Virus Research 54, 403–422.

Das, T., Pattnaik, A. K., Takacs, A. M., Li, T., Hwang, L. N. & Banerjee, A. K. (1997). Basic amino acid residues at the carboxy-terminal eleven amino acid region of the phosphoprotein (P) are required for transcription but not for replication of vesicular stomatitis virus genome RNA. Virology 238, 103–114.

Das, T., Chakrabarti, B. K., Chattopadhyay, D. & Banerjee, A. K. (1999). Carboxy-terminal five amino acids of the nucleocapsid protein of vesicular stomatitis virus are required for encapsidation and replication of genome RNA. Virology 259, 219–227.

Das, S. C., Baron, M. D. & Barrett, T. (2000). Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability. Journal of Virology 74, 9039–9047.

De, B. P., Gupta, S. & Banerjee, A. K. (1995). Cellular protein kinase C isoform regulates human parainfluenza virus type 3 replication. Proceedings of the National Academy of Sciences, USA 92, 5204–5208.

De, B. P., Hoffman, M. A., Choudhary, S., Huntley, C. C. & Banerjee, A. K. (2000). Role of NH₂- and COOH-terminal domains of the P protein of human parainfluenza virus type 3 in transcription and replication. Journal of Virology 74, 5886–5895.

de la Torre, J. C. (2001). Bornaviridae. In Fields Virology, 4th edn, pp. 1669–1678. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Delenda, C., Hausmann, S., Garcin, D. & Kolakofsky, D. (1997). Normal cellular replication of Sendai virus without the trans-frame, nonstructural V protein. Virology 228, 55–62.

Delenda, C., Taylor, G., Hausmann, S., Garcin, D. & Kolakofsky, D. (1998). Sendai viruses with altered P, V, and W protein expression. Virology 242, 327–337.

Didcock, L., Young, D. F., Goodbourn, S. & Randall, R. E. (1999a). Sendai virus and simian virus 5 block activation of interferon-responsive genes: importance for virus pathogenesis. Journal of Virology 73, 3125–3133.

Didcock, L., Young, D. F., Goodbourn, S. & Randall, R. E. (1999b). The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. Journal of Virology 73, 9928–9933.

Dimock, K. & Collins, P. L. (1993). Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3. Journal of Virology 67, 2772–2778.

Donnelly, M. L., Hughes, L. E., Luke, G., Mendoza, H., ten Dam, E., Gani, D. & Ryan, M. D. (2001). The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. Journal of General Virology 82, 1027–1041.

Dunn, E. F., Pritlove, D. C., Jin, H. & Elliott, R. M. (1995). Transcription of a recombinant bunyavirus RNA template by transiently expressed bunyavirus proteins. Virology 211, 133–143.

Duprex, W. P., Duffy, I., McQuaid, S., Hamill, L., Cosby, S. L., Billeter, M. A., Schneider-Schaulies, J., ter Meulen, V. & Rima, B. K. (1999). The H gene of rodent brain-adapted measles virus confers neurovirulence to the Edmonston vaccine strain. Journal of Virology 73, 6916–6922.

Durbin, A. P., Hall, S. L., Siew, J. W., Whitehead, S. S., Collins, P. L. & Murphy, B. R. (1997a). Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235, 323–332.

Durbin, A. P., Siew, J. W., Murphy, B. R. & Collins, P. L. (1997b). Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 234, 74–83.

Durbin, A. P., McAuliffe, J. M., Collins, P. L. & Murphy, B. R. (1999). Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261, 319–330.

Durbin, A. P., Skiadopoulos, M. H., McAuliffe, J. M., Riggs, J. M., Surman, S. R., Collins, P. L. & Murphy, B. R. (2000). Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. Journal of Virology 74, 6821–6831.

Enami, M., Luytjes, W., Krystal, M. & Palese, P. (1990). Introduction of site-specific mutations into the genome of influenza virus. Proceedings of the National Academy of Sciences, USA 87, 3802–3805.

Escoffier, C., Manie, S., Vincent, S., Muller, C. P., Billeter, M. & Gerlier, D. (1999). Nonstructural C protein is required for efficient measles virus replication in human peripheral blood cells. Journal of Virology 73, 1695–1698.

Fearns, R. & Collins, P. L. (1999). Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. Journal of Virology 73, 5852–5864.

Fearns, R., Peeples, M. E. & Collins, P. L. (1997). Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 236, 188–201.

Fearns, R., Collins, P. L. & Peeples, M. E. (2000). Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus. Journal of Virology 74, 6006–6014.

Finke, S. & Conzelmann, K. K. (1999). Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3´ copy-back ambisense rabies virus. Journal of Virology 73, 3818–3825.

Finke, S., Cox, J. H. & Conzelmann, K. K. (2000). Differential transcription attenuation of rabies virus genes by intergenic regions: generation of recombinant viruses overexpressing the polymerase gene. Journal of Virology 74, 7261–7269.

Flanagan, E. B., Ball, L. A. & Wertz, G. W. (2000). Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. Journal of Virology 74, 7895–7902.

Flanagan, E. B., Zamparo, J. M., Ball, L. A., Rodriguez, L. L. & Wertz, G. W. (2001). Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. Journal of Virology 75, 6107–6114.

Flick, R. & Hobom, G. (1999). Interaction of influenza virus polymerase with viral RNA in the 'corkscrew' conformation. Journal of General Virology 80, 2565–2572.

Flick, R. & Pettersson, R. F. (2001). Reverse genetics system for Uukuniemi virus (Bunyaviridae): RNA polymerase I-catalyzed expression of chimeric viral RNAs. Journal of Virology 75, 1643–1655.

Flick, R., Neumann, G., Hoffmann, E., Neumeier, E. & Hobom, G. (1996). Promoter elements in the influenza vRNA terminal structure. RNA 2, 1046–1057.

Fodor, E., Seong, B. L. & Brownlee, G. G. (1993). Photochemical cross-linking of influenza A polymerase to its virion RNA promoter defines a polymerase binding site at residues 9 to 12 of the promoter. Journal of General Virology 74, 1327–1333.

Fodor, E., Pritlove, D. C. & Brownlee, G. G. (1994). The influenza virus panhandle is involved in the initiation of transcription. Journal of Virology 68, 4092–4096.

Fodor, E., Pritlove, D. C. & Brownlee, G. G. (1995). Characterization of the RNA-fork model of virion RNA in the initiation of transcription in influenza A virus. Journal of Virology 69, 4012–4019.

Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G. & Garcia-Sastre, A. (1999). Rescue of influenza A virus from recombinant DNA. Journal of Virology 73, 9679–9682.

Fouillot-Coriou, N. & Roux, L. (2000). Structure-function analysis of the Sendai virus F and HN cytoplasmic domain: different role for the two proteins in the production of virus particle. Virology 270, 464–475.

Garcia-Sastre, A. (2000). Transfectant influenza viruses as antigen delivery vectors. Advances in Virus Research 55, 579–597.

Garcia-Sastre, A. (2001). Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 279, 375–384.

Garcia-Sastre, A. & Palese, P. (1993). Genetic manipulation of negative-strand RNA virus genomes. Annual Review of Microbiology 47, 765–790.

Garcia-Sastre, A. & Palese, P. (1995). The cytoplasmic tail of the neuraminidase protein on influenza A virus does not play an important role in the packaging of this protein into viral envelopes. Virus Research 37, 37–47.

Garcia-Sastre, A., Muster, T., Barclay, W. S., Percy, N. & Palese, P. (1994a). Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. Journal of Virology 68, 6254–6261.

Garcia-Sastre, A., Percy, N., Barclay, W. & Palese, P. (1994b). Introduction of foreign sequences into the genome of influenza A virus. Developments in Biological Standardization 82, 237–246.

Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D. E., Durbin, J. E., Palese, P. & Muster, T. (1998). Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324–330.

Garcin, D., Pelet, T., Calain, P., Roux, L., Curran, J. & Kolakofsky, D. (1995). A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO Journal 14, 6087–6094.

Garcin, D., Itoh, M. & Kolakofsky, D. (1997). A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology 238, 424–431.

Garcin, D., Latorre, P. & Kolakofsky, D. (1999). Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state. Journal of Virology 73, 6559–6565.

Garcin, D., Curran, J. & Kolakofsky, D. (2000). Sendai virus C proteins must interact directly with cellular components to interfere with interferon action. Journal of Virology 74, 8823–8830.

Garcin, D., Curran, J., Itoh, M. & Kolakofsky, D. (2001). Longer and shorter forms of Sendai virus C proteins play different roles in modulating the cellular antiviral response. Journal of Virology 75, 6800–6807.

Gassen, U., Collins, F. M., Duprex, W. P. & Rima, B. K. (2000). Establishment of a rescue system for canine distemper virus. Journal of Virology 74, 10737–10744.

Gilleland, H. E., Jr, Gilleland, L. B., Staczek, J., Harty, R. N., Garcia-Sastre, A., Engelhardt, O. G. & Palese, P. (1997). Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. Behring Institute Mitteilungen 98, 291–301.

Gomez-Puertas, P., Mena, I., Castillo, M., Vivo, A., Perez-Pastrana, E. & Portela, A. (1999). Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. Journal of General Virology 80, 1635–1645.

Gomez-Puertas, P., Albo, C., Perez-Pastrana, E., Vivo, A. & Portela, A. (2000). Influenza virus matrix protein is the major driving force in virus budding. Journal of Virology 74, 11538–11547.

Goto, H. & Kawaoka, Y. (1998). A novel mechanism for the acquisition of virulence by a human influenza A virus. Proceedings of the National Academy of Sciences, USA 95, 10224–10228.

Goto, H., Wells, K., Takada, A. & Kawaoka, Y. (2001). Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. Journal of Virology 75, 9297–9301.

Gotoh, B., Takeuchi, K., Komatsu, T., Yokoo, J., Kimura, Y., Kurotani, A., Kato, A. & Nagai, Y. (1999). Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-/-mediated responses. FEBS Letters 459, 205–210.

Haglund, K., Forman, J., Krausslich, H. G. & Rose, J. K. (2000). Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268, 112–121.

Haller, A. A., Miller, T., Mitiku, M. & Coelingh, K. (2000). Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. Journal of Virology 74, 11626–11635.

Hardy, R. W. & Wertz, G. W. (1998). The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. Journal of Virology 72, 520–526.

Hardy, R. W., Harmon, S. B. & Wertz, G. W. (1999). Diverse gene junctions of respiratory syncytial virus modulate the efficiency of transcription termination and respond differently to M2-mediated antitermination. Journal of Virology 73, 170–176.

Harty, R. N. & Palese, P. (1995). Mutations within noncoding terminal sequences of model RNAs of Sendai virus: influence on reporter gene expression. Journal of Virology 69, 5128–5131.

Hasan, M. K., Kato, A., Shioda, T., Sakai, Y., Yu, D. & Nagai, Y. (1997). Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3´ proximal first locus. Journal of General Virology 78, 2813–2820.

Hasan, M. K., Kato, A., Muranaka, M., Yamaguchi, R., Sakai, Y., Hatano, I., Tashiro, M. & Nagai, Y. (2000). Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role. Journal of Virology 74, 5619–5628.

Hatada, E., Saito, S. & Fukuda, R. (1999). Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. Journal of Virology 73, 2425–2433.

Hatta, M., Gao, P., Halfmann, P. & Kawaoka, Y. (2001). Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293, 1840–1842.

Hausmann, S., Jacques, J. P. & Kolakofsky, D. (1996). Paramyxovirus RNA editing and the requirement for hexamer genome length. RNA 2, 1033–1045.

He, B. & Lamb, R. A. (1999). Effect of inserting paramyxovirus simian virus 5 gene junctions at the HN/L gene junction: analysis of accumulation of mRNAs transcribed from rescued viable viruses. Journal of Virology 73, 6228–6234.

He, B., Paterson, R. G., Ward, C. D. & Lamb, R. A. (1997). Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237, 249–260.

He, B., Leser, G. P., Paterson, R. G. & Lamb, R. A. (1998). The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology 250, 30–40.

He, B., Lin, G. Y., Durbin, J. E., Durbin, R. K. & Lamb, R. A. (2001). The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. Journal of Virology 75, 4068–4079.

Herlocher, M. L., Clavo, A. C. & Maassab, H. F. (1996). Sequence comparisons of A/AA/6/60 influenza viruses: mutations which may contribute to attenuation. Virus Research 42, 11–25.

Hoffman, M. A. & Banerjee, A. K. (1997). An infectious clone of human parainfluenza virus type 3. Journal of Virology 71, 4272–4277.

Hoffman, M. A. & Banerjee, A. K. (2000a). Analysis of RNA secondary structure in replication of human parainfluenza virus type 3. Virology 272, 151–158.

Hoffman, M. A. & Banerjee, A. K. (2000b). Precise mapping of the replication and transcription promoters of human parainfluenza virus type 3. Virology 269, 201–211.

Hoffmann, E. & Webster, R. G. (2000). Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids. Journal of General Virology 81, 2843–2847.

Hoffmann, E., Neumann, G., Hobom, G., Webster, R. G. & Kawaoka, Y. (2000a). 'Ambisense' approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267, 310–317.

Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. (2000b). A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences, USA 97, 6108–6113.

Honda, A., Ueda, K., Nagata, K. & Ishihama, A. (1987). Identification of the RNA polymerase-binding site on genome RNA of influenza virus. Journal of Biochemistry 102, 1241–1249.

Honda, A., Ueda, K., Nagata, K. & Ishihama, A. (1988). RNA polymerase of influenza virus: role of NP in RNA chain elongation. Journal of Biochemistry 104, 1021–1026.

Honda, A., Mukaigawa, J., Yokoiyama, A., Kato, A., Ueda, S., Nagata, K., Krystal, M., Nayak, D. P. & Ishihama, A. (1990). Purification and molecular structure of RNA polymerase from influenza virus A/PR8. Journal of Biochemistry 107, 624–628.

Horikami, S. M., Curran, J., Kolakofsky, D. & Moyer, S. A. (1992). Complexes of Sendai virus NP–P and P–L proteins are required for defective interfering particle genome replication in vitro. Journal of Virology 66, 4901–4908.

Horimoto, T. & Kawaoka, Y. (1994). Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. Journal of Virology 68, 3120–3128.

Hsu, M. T., Parvin, J. D., Gupta, S., Krystal, M. & Palese, P. (1987). Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. Proceedings of the National Academy of Sciences, USA 84, 8140–8144.

Hu, C. J., Kato, A., Bowman, M. C., Kiyotani, K., Yoshida, T., Moyer, S. A., Nagai, Y. & Gupta, K. C. (1999). Role of primary constitutive phosphorylation of Sendai virus P and V proteins in viral replication and pathogenesis. Virology 263, 195–208.

Huang, C., Kiyotani, K., Fujii, Y., Fukuhara, N., Kato, A., Nagai, Y., Yoshida, T. & Sakaguchi, T. (2000). Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis. Journal of Virology 74, 7834–7841.

Hwang, L. N., Englund, N. & Pattnaik, A. K. (1998). Polyadenylation of vesicular stomatitis virus mRNA dictates efficient transcription termination at the intercistronic gene junctions. Journal of Virology 72, 1805–1813.

Hwang, L. N., Englund, N., Das, T., Banerjee, A. K. & Pattnaik, A. K. (1999). Optimal replication activity of vesicular stomatitis virus RNA polymerase requires phosphorylation of a residue(s) at carboxy-terminal domain II of its accessory subunit, phosphoprotein P. Journal of Virology 73, 5613–5620.

Isobe, H., Moran, T., Li, S., Young, A., Nathenson, S., Palese, P. & Bona, C. (1995). Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant. Journal of Experimental Medicine 181, 203–213.

Ito, N., Takayama, M., Yamada, K., Sugiyama, M. & Minamoto, N. (2001). Rescue of rabies virus from cloned cDNA and identification of the pathogenicity-related gene: glycoprotein gene is associated with virulence for adult mice. Journal of Virology 75, 9121–9128.

Jayakar, H. R., Murti, K. G. & Whitt, M. A. (2000). Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. Journal of Virology 74, 9818–9827.

Jin, H., Leser, G. P. & Lamb, R. A. (1994). The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity. EMBO Journal 13, 5504–5515.

Jin, H., Subbarao, K., Bagai, S., Leser, G. P., Murphy, B. R. & Lamb, R. A. (1996). Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity. Journal of Virology 70, 1406–1414.

Jin, H., Leser, G. P., Zhang, J. & Lamb, R. A. (1997). Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO Journal 16, 1236–1247.

Jin, H., Cheng, X., Zhou, H. Z., Li, S. & Seddiqui, A. (2000a). Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. Journal of Virology 74, 74–82.

Jin, H., Zhou, H., Cheng, X., Tang, R., Munoz, M. & Nguyen, N. (2000b). Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273, 210–218.

Johnson, J. E., Schnell, M. J., Buonocore, L. & Rose, J. K. (1997). Specific targeting to CD4⁺ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. Journal of Virology 71, 5060–5068.

Johnston, I. C., ter Meulen, V., Schneider-Schaulies, J. & Schneider-Schaulies, S. (1999). A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism. Journal of Virology 73, 6903–6915.

Juhasz, K., Whitehead, S. S., Bui, P. T., Biggs, J. M., Crowe, J. E., Boulanger, C. A., Collins, P. L. & Murphy, B. R. (1997). The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. Journal of Virology 71, 5814–5819.

Juhasz, K., Murphy, B. R. & Collins, P. L. (1999a). The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. Journal of Virology 73, 5176–5180.

Juhasz, K., Whitehead, S. S., Boulanger, C. A., Firestone, C. Y., Collins, P. L. & Murphy, B. R. (1999b). The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 17, 1416–1424.

Kahn, J. S., Schnell, M. J., Buonocore, L. & Rose, J. K. (1999). Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254, 81–91.

Karger, A., Schmidt, U. & Buchholz, U. J. (2001). Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. Journal of General Virology 82, 631–640.

Karron, R. A., Buonagurio, D. A., Georgiu, A. F., Whitehead, S. S., Adamus, J. E., Clements-Mann, M. L., Harris, D. O., Randolph, V. B., Udem, S. A., Murphy, B. R. & Sidhu, M. S. (1997a). Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proceedings of the National Academy of Sciences, USA 94, 13961–13966.

Karron, R. A., Wright, P. F., Crowe, J. E., Jr, Clements-Mann, M. L., Thompson, J., Makhene, M., Casey, R. & Murphy, B. R. (1997b). Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Journal of Infectious Diseases 176, 1428–1436.

Kato, A., Sakai, Y., Shioda, T., Kondo, T., Nakanishi, M. & Nagai, Y. (1996). Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes to Cells 1, 569–579.

Kato, A., Kiyotani, K., Sakai, Y., Yoshida, T. & Nagai, Y. (1997a). The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO Journal 16, 578–587.

Kato, A., Kiyotani, K., Sakai, Y., Yoshida, T., Shioda, T. & Nagai, Y. (1997b). Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. Journal of Virology 71, 7266–7272.

Kato, A., Kiyotani, K., Hasan, M. K., Shioda, T., Sakai, Y., Yoshida, T. & Nagai, Y. (1999). Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene. Journal of Virology 73, 9237–9246.

Kato, A., Ohnishi, Y., Kohase, M., Saito, S., Tashiro, M. & Nagai, Y. (2001). Y2, the smallest of the Sendai virus C proteins, is fully capable of both counteracting the antiviral action of interferons and inhibiting viral RNA synthesis. Journal of Virology 75, 3802–3810.

Kawano, M., Kaito, M., Kozuka, Y., Komada, H., Noda, N., Nanba, K., Tsurudome, M., Ito, M., Nishio, M. & Ito, Y. (2001). Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology 284, 99–112.

Kawaoka, Y. & Webster, R. G. (1988). Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proceedings of the National Academy of Sciences, USA 85, 324–328.

Kawaoka, Y. & Webster, R. G. (1989). Interplay between carbohydrate in the stalk and the length of the connecting peptide determines the cleavability of influenza virus hemagglutinin. Journal of Virology 63, 3296–3300.

Keller, M. A., Murphy, S. K. & Parks, G. D. (2001). RNA replication from the simian virus 5 antigenomic promoter requires three sequence-dependent elements separated by sequence-independent spacer regions. Journal of Virology 75, 3993–3998.

Kim, H. J., Fodor, E., Brownlee, G. G. & Seong, B. L. (1997). Mutational analysis of the RNA-fork model of the influenza A virus vRNA promoter in vivo. Journal of General Virology 78, 353–357.

Klenk, H. D. & Garten, W. (1994). Host cell proteases controlling virus pathogenicity. Trends in Microbiology 2, 39–43.

Knipe, D. M. & Howley, P. M. (editors) (2001). Fields Virology, 4th edn. Philadelphia: Lippincott Williams & Wilkins.

Kolakofsky, D., Pelet, T., Garcin, D., Hausmann, S., Curran, J. & Roux, L. (1998). Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. Journal of Virology 72, 891–899.

Kretzschmar, E., Peluso, R., Schnell, M. J., Whitt, M. A. & Rose, J. K. (1996). Normal replication of vesicular stomatitis virus without C proteins. Virology 216, 309–316.

Kretzschmar, E., Buonocore, L., Schnell, M. J. & Rose, J. K. (1997). High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. Journal of Virology 71, 5982–5989.

Krishnamurthy, S., Huang, Z. & Samal, S. K. (2000). Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278, 168–182.

Kuo, L., Fearns, R. & Collins, P. L. (1996a). The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome. Journal of Virology 70, 6143–6150.

Kuo, L., Grosfeld, H., Cristina, J., Hill, M. G. & Collins, P. L. (1996b). Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. Journal of Virology 70, 6892–6901.

Kuo, L., Fearns, R. & Collins, P. L. (1997). Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA. Journal of Virology 71, 4944–4953.

Kurotani, A., Kiyotani, K., Kato, A., Shioda, T., Sakai, Y., Mizumoto, K., Yoshida, T. & Nagai, Y. (1998). Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes to Cells 3, 111–124.

Lamb, R. A. & Kolakofsky, D. (2001). Paramyxoviridae: The viruses and their replication. In Fields Virology, 4th edn, pp. 1305–1340. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Lamb, R. A. & Krug, R. M. (2001). Orthomyxoviridae: The viruses and their replication. In Fields Virology, 4th edn, pp. 1487–1532. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Latham, T. & Galarza, J. M. (2001). Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. Journal of Virology 75, 6154–6165.

Latorre, P., Cadd, T., Itoh, M., Curran, J. & Kolakofsky, D. (1998a). The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection. Journal of Virology 72, 5984–5993.

Latorre, P., Kolakofsky, D. & Curran, J. (1998b). Sendai virus Y proteins are initiated by a ribosomal shunt. Molecular and Cellular Biology 18, 5021–5031.

Lawson, N. D., Stillman, E. A., Whitt, M. A. & Rose, J. K. (1995). Recombinant vesicular stomatitis viruses from DNA. Proceedings of the National Academy of Sciences, USA 92, 4477–4481.

Leahy, M. B., Dobbyn, H. C. & Brownlee, G. G. (2001a). Hairpin loop structure in the 3´ arm of the influenza a virus virion RNA promoter is required for endonuclease activity. Journal of Virology 75, 7042–7049.

Leahy, M. B., Pritlove, D. C., Poon, L. L. & Brownlee, G. G. (2001b). Mutagenic analysis of the 5´ arm of the influenza A virus virion RNA promoter defines the sequence requirements for endonuclease activity. Journal of Virology 75, 134–142.

Lee, Y. S. & Seong, B. L. (1996). Mutational analysis of influenza B virus RNA transcription in vitro. Journal of Virology 70, 1232–1236.

Lee, K. J., Novella, I. S., Teng, M. N., Oldstone, M. B. & de la Torre, J. C. (2000). NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. Journal of Virology 74, 3470–3477.

Li, X. & Palese, P. (1992). Mutational analysis of the promoter required for influenza virus virion RNA synthesis. Journal of Virology 66, 4331–4338.

Li, X. & Palese, P. (1994). Characterization of the polyadenylation signal of influenza virus RNA. Journal of Virology 68, 1245–1249.

Li, T. & Pattnaik, A. K. (1997). Replication signals in the genome of vesicular stomatitis virus and its defective interfering particles: identification of a sequence element that enhances DI RNA replication. Virology 232, 248–259.

Li, T. & Pattnaik, A. K. (1999). Overlapping signals for transcription and replication at the 3´ terminus of the vesicular stomatitis virus genome. Journal of Virology 73, 444–452.Lin, G. Y. & Lamb, R. A. (2000). The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. Journal of Virology 74, 9152–9166.

Li, S. Q., Schulman, J. L., Moran, T., Bona, C. & Palese, P. (1992). Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. Journal of Virology 66, 399–404.

Li, S., Polonis, V., Isobe, H., Zaghouani, H., Guinea, R., Moran, T., Bona, C. & Palese, P. (1993a). Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. Journal of Virology 67, 6659–6666.

Li, S., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Esteban, M., Palese, P., Nussenzweig, R. S. & Zavala, F. (1993b). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8⁺ T-cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences, USA 90, 5214–5218.

Li, S., Schulman, J., Itamura, S. & Palese, P. (1993c). Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. Journal of Virology 67, 6667–6673.

Li, H. O., Zhu, Y. F., Asakawa, M., Kuma, H., Hirata, T., Ueda, Y., Lee, Y. S., Fukumura, M., Iida, A., Kato, A., Nagai, Y. & Hasegawa, M. (2000). A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. Journal of Virology 74, 6564–6569.

Lin, G. Y. & Lamb, R. A. (2000). The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. Journal of Virology 74, 9152–9166.

Lin, Y. P., Wharton, S. A., Martin, J., Skehel, J. J., Wiley, D. C. & Steinhauer, D. A. (1997). Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 233, 402–410.

Lin, G. Y., Paterson, R. G., Richardson, C. D. & Lamb, R. A. (1998). The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein. Virology 249, 189–200.

Lopez, N., Muller, R., Prehaud, C. & Bouloy, M. (1995). The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules. Journal of Virology 69, 3972–3979.

Luo, G. X., Luytjes, W., Enami, M. & Palese, P. (1991). The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure. Journal of Virology 65, 2861–2867.

Luo, G., Chung, J. & Palese, P. (1993). Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Research 29, 141–153.

Luytjes, W., Krystal, M., Enami, M., Pavin, J. D. & Palese, P. (1989). Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59, 1107–1113.

Maassab, H. F. & Bryant, M. L. (1999). The development of live attenuated cold-adapted influenza virus vaccine for humans. Reviews in Medical Virology 9, 237–244.

Maisner, A., Mrkic, B., Herrler, G., Moll, M., Billeter, M. A., Cattaneo, R. & Klenk, H. D. (2000). Recombinant measles virus requiring an exogenous protease for activation of infectivity. Journal of General Virology 81, 441–449.

Marriott, A. C. & Easton, A. J. (1999). Reverse genetics of the Paramyxoviridae. Advances in Virus Research 53, 321–340.

Mebatsion, T. & Conzelmann, K. K. (1996). Specific infection of CD4⁺ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proceedings of the National Academy of Sciences, USA 93, 11366–11370.

Mebatsion, T., Schnell, M. J., Cox, J. H., Finke, S. & Conzelmann, K. K. (1996). Highly stable expression of a foreign gene from rabies virus vectors. Proceedings of the National Academy of Sciences, USA 93, 7310–7314.

Mebatsion, T., Finke, S., Weiland, F. & Conzelmann, K. K. (1997). A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90, 841–847.

Mebatsion, T., Weiland, F. & Conzelmann, K. K. (1999). Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. Journal of Virology 73, 242–250.

Mebatsion, T., Verstegen, S., De Vaan, L. T., Romer-Oberdorfer, A. & Schrier, C. C. (2001). A recombinant Newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos. Journal of Virology 75, 420–428.

Mena, I., Vivo, A., Perez, E. & Portela, A. (1996). Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids. Journal of Virology 70, 5016–5024.

Mitnaul, L. J., Castrucci, M. R., Murti, K. G. & Kawaoka, Y. (1996). The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication. Journal of Virology 70, 873–879.

Moll, M., Klenk, H. D., Herrler, G. & Maisner, A. (2001). A single amino acid change in the cytoplasmic domains of measles virus glycoproteins H and F alters targeting, endocytosis, and cell fusion in polarized Madin–Darby canine kidney cells. Journal of Biological Chemistry 276, 17887–17894.

Morimoto, K., Foley, H. D., McGettigan, J. P., Schnell, M. J. & Dietzschold, B. (2000). Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. Journal of Neurovirology 6, 373–381.

Muhlberger, E., Lotfering, B., Klenk, H. D. & Becker, S. (1998). Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. Journal of Virology 72, 8756–8764.

Muhlberger, E., Weik, M., Volchkov, V. E., Klenk, H. D. & Becker, S. (1999). Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. Journal of Virology 73, 2333–2342.

Munoz, F. M., Galasso, G. J., Gwaltney, J. M., Jr, Hayden, F. G., Murphy, B., Webster, R., Wright, P. & Couch, R. B. (2000). Current research on influenza and other respiratory viruses. II. International Symposium. Antiviral Research 46, 91–124.

Murata, K., Garcia-Sastre, A., Tsuji, M., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Nussenzweig, R. S., Palese, P., Esteban, M. & Zavala, F. (1996). Characterization of in vivo primary and secondary CD8⁺ T cell responses induced by recombinant influenza and vaccinia viruses. Cellular Immunology 173, 96–107.

Murphy, S. K. & Parks, G. D. (1997). Genome nucleotide lengths that are divisible by six are not essential but enhance replication of defective interfering RNAs of the paramyxovirus simian virus 5. Virology 232, 145–157.

Murphy, S. K. & Parks, G. D. (1999). RNA replication for the paramyxovirus simian virus 5 requires an internal repeated (CGNNNN) sequence motif. Journal of Virology 73, 805–809.

Murphy, S. K., Ito, Y. & Parks, G. D. (1998). A functional antigenomic promoter for the paramyxovirus simian virus 5 requires proper spacing between an essential internal segment and the 3´ terminus. Journal of Virology 72, 10–19.

Muster, T., Guinea, R., Trkola, A., Purtscher, M., Klima, A., Steindl, F., Palese, P. & Katinger, H. (1994). Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. Journal of Virology 68, 4031–4034.

Muster, T., Ferko, B., Klima, A., Purtscher, M., Trkola, A., Schulz, P., Grassauer, A., Engelhardt, O. G., Garcia-Sastre, A., Palese, P. and others (1995). Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. Journal of Virology 69, 6678–6686.

Nagai, Y. (1999). Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Reviews in Medical Virology 9, 83–99.

Nagai, Y. & Kato, A. (1999). Paramyxovirus reverse genetics is coming of age. Microbiology and Immunology 43, 613–624.

Neumann, G. & Hobom, G. (1995). Mutational analysis of influenza virus promoter elements in vivo. Journal of General Virology 76, 1709–1717.

Neumann, G. & Kawaoka, Y. (1999). Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Advances in Virus Research 53, 265–300.

Neumann, G. & Kawaoka, Y. (2001). Reverse genetics of influenza virus. Virology 287, 243–250.

Neumann, G., Zobel, A. & Hobom, G. (1994). RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202, 477–479.

Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., Hobom, G. & Kawaoka, Y. (1999). Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences, USA 96, 9345–9350.

Neumann, G., Hughes, M. T. & Kawaoka, Y. (2000a). Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO Journal 19, 6751–6758.

Neumann, G., Watanabe, T. & Kawaoka, Y. (2000b). Plasmid-driven formation of influenza virus-like particles. Journal of Virology 74, 547–551.

Neumann, G., Feldmann, H., Watanabe, S., Lukashevich, I. & Kawaoka, Y. (2002). Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. Journal of Virology 76, 406–410.

Ohgimoto, S., Ohgimoto, K., Niewiesk, S., Klagge, I. M., Pfeuffer, J., Johnston, I. C., Schneider-Schaulies, J., Weidmann, A., ter Meulen, V. & Schneider-Schaulies, S. (2001). The haemagglutinin protein is an important determinant of measles virus tropism for dendritic cells in vitro. Journal of General Virology 82, 1835–1844.

O'Neill, R. E., Talon, J. & Palese, P. (1998). The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO Journal 17, 288–296.

Palese, P. (1995). Genetic engineering of infectious negative-strand RNA viruses. Trends in Microbiology 3, 123–125.

Palese, P., Zheng, H., Engelhardt, O. G., Pleschka, S. & Garcia-Sastre, A. (1996). Negative-strand RNA viruses: genetic engineering and application. Proceedings of the National Academy of Sciences, USA 93, 11354–11358.

Parisien, J. P., Lau, J. F., Rodriguez, J. J., Sullivan, B. M., Moscona, A., Parks, G. D., Lamb, R. A. & Horvath, C. M. (2001). The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 283, 230–239.

Park, K. H., Huang, T., Correia, F. F. & Krystal, M. (1991). Rescue of a foreign gene by Sendai virus. Proceedings of the National Academy of Sciences, USA 88, 5537–5541.

Parkin, N. T., Chiu, P. & Coelingh, K. L. (1996). Temperature sensitive mutants of influenza A virus generated by reverse genetics and clustered charged to alanine mutagenesis. Virus Research 46, 31–44.

Parkin, N. T., Chiu, P. & Coelingh, K. (1997). Genetically engineered live attenuated influenza A virus vaccine candidates. Journal of Virology 71, 2772–2778.

Parks, C. L., Lerch, R. A., Walpita, P., Sidhu, M. S. & Udem, S. A. (1999). Enhanced measles virus cDNA rescue and gene expression after heat shock. Journal of Virology 73, 3560–3566.

Parvin, J. D., Palese, P., Honda, A., Ishihama, A. & Krystal, M. (1989). Promoter analysis of influenza virus RNA polymerase. Journal of Virology 63, 5142–5152.

Patterson, J. B., Thomas, D., Lewicki, H., Billeter, M. A. & Oldstone, M. B. (2000). V and C proteins of measles virus function as virulence factors in vivo. Virology 267, 80–89.

Pattnaik, A. K. & Wertz, G. W. (1990). Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs. Journal of Virology 64, 2948–2957.

Pattnaik, A. K. & Wertz, G. W. (1991). Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles. Proceedings of the National Academy of Sciences, USA 88, 1379–1383.

Pattnaik, A. K., Ball, L. A., LeGrone, A. & Wertz, G. W. (1995). The termini of VSV DI particle RNAs are sufficient to signal RNA encapsidation, replication, and budding to generate infectious particles. Virology 206, 760–764.

Pattnaik, A. K., Hwang, L., Li, T., Englund, N., Mathur, M., Das, T. & Banerjee, A. K. (1997). Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication. Journal of Virology 71, 8167–8175.

Peeples, M. E. & Collins, P. L. (2000). Mutations in the 5´ trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step. Journal of Virology 74, 146–155.

Peeters, B. P., de Leeuw, O. S., Koch, G. & Gielkens, A. L. (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. Journal of Virology 73, 5001–5009.

Peeters, B. P., Gruijthuijsen, Y. K., de Leeuw, O. S. & Gielkens, A. L. (2000). Genome replication of Newcastle disease virus: involvement of the rule-of-six. Archives of Virology 145, 1829–1845.

Peeters, B. P., de Leeuw, O. S., Verstegen, I., Koch, G. & Gielkens, A. L. (2001). Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19, 1616–1627.

Pekosz, A., He, B. & Lamb, R. A. (1999). Reverse genetics of negative-strand RNA viruses: closing the circle. Proceedings of the National Academy of Sciences, USA 96, 8804–8806.

Pelet, T., Delenda, C., Gubbay, O., Garcin, D. & Kolakofsky, D. (1996). Partial characterization of a Sendai virus replication promoter and the rule of six. Virology 224, 405–414.

Percy, N., Barclay, W. S., Garcia-Sastre, A. & Palese, P. (1994). Expression of a foreign protein by influenza A virus. Journal of Virology 68, 4486–4492.

Piccone, M. E., Fernandez-Sesma, A. & Palese, P. (1993). Mutational analysis of the influenza virus vRNA promoter. Virus Research 28, 99–112.

Poon, L. L., Fodor, E. & Brownlee, G. G. (2000). Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export. Journal of Virology 74, 418–427.

Pritlove, D. C., Fodor, E., Seong, B. L. & Brownlee, G. G. (1995). In vitro transcription and polymerase binding studies of the termini of influenza A virus cRNA: evidence for a cRNA panhandle. Journal of General Virology 76, 2205–2213.

Pritlove, D. C., Poon, L. L., Devenish, L. J., Leahy, M. B. & Brownlee, G. G. (1999). A hairpin loop at the 5´ end of influenza A virus virion RNA is required for synthesis of poly(A)⁺ mRNA in vitro. Journal of Virology 73, 2109–2114.

Racaniello, V. R. & Baltimore, D. (1981). Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214, 916–919.

Radecke, F. & Billeter, M. A. (1996). The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells. Virology 217, 418–421.

Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch, C., Christiansen, G. & Billeter, M. A. (1995). Rescue of measles viruses from cloned DNA. EMBO Journal 14, 5773–5784.

Rassa, J. C. & Parks, G. D. (1999). Highly diverse intergenic regions of the paramyxovirus simian virus 5 cooperate with the gene end U tract in viral transcription termination and can influence reinitiation at a downstream gene. Journal of Virology 73, 3904–3912.

Rassa, J. C., Wilson, G. M., Brewer, G. A. & Parks, G. D. (2000). Spacing constraints on reinitiation of paramyxovirus transcription: the gene end U tract acts as a spacer to separate gene end from gene start sites. Virology 274, 438–449.

Reutter, G. L., Cortese-Grogan, C., Wilson, J. & Moyer, S. A. (2001). Mutations in the measles virus C protein that up regulate viral RNA synthesis. Virology 285, 100–109.

Roberts, A. & Rose, J. K. (1998). Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field. Virology 247, 1–6.

Roberts, A. & Rose, J. K. (1999). Redesign and genetic dissection of the rhabdoviruses. Advances in Virus Research 53, 301–319.

Roberts, A., Kretzschmar, E., Perkins, A. S., Forman, J., Price, R., Buonocore, L., Kawaoka, Y. & Rose, J. K. (1998). Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. Journal of Virology 72, 4704–4711.

Roberts, A., Buonocore, L., Price, R., Forman, J. & Rose, J. K. (1999). Attenuated vesicular stomatitis viruses as vaccine vectors. Journal of Virology 73, 3723–3732.

Robison, C. S. & Whitt, M. A. (2000). The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. Journal of Virology 74, 2239–2246.

Romer-Oberdorfer, A., Mundt, E., Mebatsion, T., Buchholz, U. J. & Mettenleiter, T. C. (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. Journal of General Virology 80, 2987–2995.

Rose, J. K. (1996). Positive strands to the rescue again: a segmented negative-strand RNA virus derived from cloned cDNAs. Proceedings of the National Academy of Sciences, USA 93, 14998–15000.

Rose, J. K. & Whitt, M. A. (2001). Rhabdoviridae: The viruses and their replication. In Fields Virology, 4th edn, pp. 1221–1244. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Rose, N. F., Roberts, A., Buonocore, L. & Rose, J. K. (2000). Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. Journal of Virology 74, 10903–10910.

Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., Montefiori, D., Roberts, A., Buonacore, L. & Rose, J. K. (2001). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539–549.

Sakaguchi, T., Kiyotani, K., Kato, A., Asakawa, M., Fujii, Y., Nagai, Y. & Yoshida, T. (1997). Phosphorylation of the Sendai virus M protein is not essential for virus replication either in vitro or in vivo. Virology 235, 360–366.

Sakaguchi, T., Uchiyama, T., Fujii, Y., Kiyotani, K., Kato, A., Nagai, Y., Kawai, A. & Yoshida, T. (1999). Double-layered membrane vesicles released from mammalian cells infected with Sendai virus expressing the matrix protein of vesicular stomatitis virus. Virology 263, 230–243.

Sakai, Y., Kiyotani, K., Fukumura, M., Asakawa, M., Kato, A., Shioda, T., Yoshida, T., Tanaka, A., Hasegawa, M. & Nagai, Y. (1999). Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Letters 456, 221–226.

Samal, S. K. & Collins, P. L. (1996). RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. Journal of Virology 70, 5075–5082.

Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J. & Nichol, S. T. (1996). The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proceedings of the National Academy of Sciences, USA 93, 3602–3607.

Sanchez, A., Khan, A. S., Zaki, S. R., Nabel, G. J., Ksiazek, T. G. & Peters, C. J. (2001). Filoviridae: Marburg and Ebola Viruses. In Fields Virology, 4th edn, pp. 1279–1304. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Schlender, J., Bossert, B., Buchholz, U. & Conzelmann, K. K. (2000). Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize / interferon-induced antiviral response. Journal of Virology 74, 8234–8242.

Schmaljohn, C. S. & Hooper, J. W. (2001). Bunyaviridae: The viruses and their replication. In Fields Virology, 4th edn, pp. 1581–1602. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.

Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. & Collins, P. L. (2001). Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. Journal of Virology 75, 4594–4603.

Schmitt, A. P., He, B. & Lamb, R. A. (1999). Involvement of the cytoplasmic domain of the hemagglutinin–neuraminidase protein in assembly of the paramyxovirus simian virus 5. Journal of Virology 73, 8703–8712.

Schneider, H., Kaelin, K. & Billeter, M. A. (1997a). Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology 227, 314–322.

Schneider, H., Spielhofer, P., Kaelin, K., Dotsch, C., Radecke, F., Sutter, G. & Billeter, M. A. (1997b). Rescue of measles virus using a replication-deficient vaccinia-T7 vector. Journal of Virological Methods 64, 57–64.

Schnell, M. J., Mebatsion, T. & Conzelmann, K. K. (1994). Infectious rabies viruses from cloned cDNA. EMBO Journal 13, 4195–4203.

Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E. & Rose, J. K. (1996a). Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proceedings of the National Academy of Sciences, USA 93, 11359–11365.

Schnell, M. J., Buonocore, L., Whitt, M. A. & Rose, J. K. (1996b). The minimal conserved transcription stop–start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. Journal of Virology 70, 2318–2323.

Schnell, M. J., Johnson, J. E., Buonocore, L. & Rose, J. K. (1997). Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90, 849–857.

Schnell, M. J., Buonocore, L., Boritz, E., Ghosh, H. P., Chernish, R. & Rose, J. K. (1998). Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO Journal 17, 1289–1296.

Schnell, M. J., Foley, H. D., Siler, C. A., McGettigan, J. P., Dietzschold, B. & Pomerantz, R. J. (2000). Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proceedings of the National Academy of Sciences, USA 97, 3544–3549.

Seong, B. L. & Brownlee, G. G. (1992a). A new method for reconstituting influenza polymerase and RNA in vitro: a study of the promoter elements for cRNA and vRNA synthesis in vitro and viral rescue in vivo. Virology 186, 247–260.

Seong, B. L. & Brownlee, G. G. (1992b). Nucleotides 9 to 11 of the influenza A virion RNA promoter are crucial for activity in vitro. Journal of General Virology 73, 3115–3124.

Sidhu, M. S., Chan, J., Kaelin, K., Spielhofer, P., Radecke, F., Schneider, H., Masurekar, M., Dowling, P. C., Billeter, M. A. & Udem, S. A. (1995). Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology 208, 800–807.

Singh, M. & Billeter, M. A. (1999). A recombinant measles virus expressing biologically active human interleukin-12. Journal of General Virology 80, 101–106.

Skiadopoulos, M. H., Durbin, A. P., Tatem, J. M., Wu, S. L., Paschalis, M., Tao, T., Collins, P. L. & Murphy, B. R. (1998). Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. Journal of Virology 72, 1762–1768.

Skiadopoulos, M. H., Surman, S., Tatem, J. M., Paschalis, M., Wu, S. L., Udem, S. A., Durbin, A. P., Collins, P. L. & Murphy, B. R. (1999a). Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. Journal of Virology 73, 1374–1381.

Skiadopoulos, M. H., Surman, S. R., St Claire, M., Elkins, W. R., Collins, P. L. & Murphy, B. R. (1999b). Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 260, 125–135.

Skiadopoulos, M. H., Tao, T., Surman, S. R., Collins, P. L. & Murphy, B. R. (1999c). Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18, 503–510.

Skiadopoulos, M. H., Surman, S. R., Durbin, A. P., Collins, P. L. & Murphy, B. R. (2000). Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology 272, 225–234.

Skiadopoulos, M. H., Surman, S. R., Riggs, J. M., Collins, P. L. & Murphy, B. R. (2001). A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. Journal of Virology 75, 10498–10504.

Spadafora, D., Canter, D. M., Jackson, R. L. & Perrault, J. (1996). Constitutive phosphorylation of the vesicular stomatitis virus P protein modulates polymerase complex formation but is not essential for transcription or replication. Journal of Virology 70, 4538–4548.

Spielhofer, P., Bachi, T., Fehr, T., Christiansen, G., Cattaneo, R., Kaelin, K., Billeter, M. A. & Naim, H. Y. (1998). Chimeric measles viruses with a foreign envelope. Journal of Virology 72, 2150–2159.

Stieneke-Grober, A., Vey, M., Angliker, H., Shaw, E., Thomas, G., Roberts, C., Klenk, H. D. & Garten, W. (1992). Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO Journal 11, 2407–2414.

Stillman, E. A. & Whitt, M. A. (1997). Mutational analyses of the intergenic dinucleotide and the transcriptional start sequence of vesicular stomatitis virus (VSV) define sequences required for efficient termination and initiation of VSV transcripts. Journal of Virology 71, 2127–2137.

Stillman, E. A. & Whitt, M. A. (1998). The length and sequence composition of vesicular stomatitis virus intergenic regions affect mRNA levels and the site of transcript initiation. Journal of Virology 72, 5565–5572.

Stillman, E. A. & Whitt, M. A. (1999). Transcript initiation and 5´-end modifications are separable events during vesicular stomatitis virus transcription. Journal of Virology 73, 7199–7209.

Stope, M. B., Karger, A., Schmidt, U. & Buchholz, U. J. (2001). Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin–neuraminidase and fusion proteins. Journal of Virology 75, 9367–9377.

Subbarao, E. K., Park, E. J., Lawson, C. M., Chen, A. Y. & Murphy, B. R. (1995). Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. Journal of Virology 69, 5969–5977.

Szewczyk, B., Laver, W. G. & Summers, D. F. (1988). Purification, thioredoxin renaturation, and reconstituted activity of the three subunits of the influenza A virus RNA polymerase. Proceedings of the National Academy of Sciences, USA 85, 7907–7911.

Takeda, M., Takeuchi, K., Miyajima, N., Kobune, F., Ami, Y., Nagata, N., Suzaki, Y., Nagai, Y. & Tashiro, M. (2000). Recovery of pathogenic measles virus from cloned cDNA. Journal of Virology 74, 6643–6647.

Takeda, M., Pekosz, A., Shuck, K., Pinto, L. H. & Lamb, R. A. (2002). Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. Journal of Virology 76, 1391–1399.

Takeuchi, K., Takeda, M., Miyajima, N., Kobune, F., Tanabayashi, K. & Tashiro, M. (2002). Recombinant wild-type and Edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity. Journal of Virology 76, 4891–4900.

Talon, J., Horvath, C. M., Polley, R., Basler, C. F., Muster, T., Palese, P. & Garcia-Sastre, A. (2000a). Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. Journal of Virology 74, 7989–7996.

Talon, J., Salvatore, M., O'Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., Garcia-Sastre, A. & Palese, P. (2000b). Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences, USA 97, 4309–4314.

Taniguchi, T., Palmieri, M. & Weissmann, C. (1978). QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature 247, 223–228.

Tao, T., Durbin, A. P., Whitehead, S. S., Davoodi, F., Collins, P. L. & Murphy, B. R. (1998). Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin–neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. Journal of Virology 72, 2955–2961.

Tao, T., Skiadopoulos, M. H., Durbin, A. P., Davoodi, F., Collins, P. L. & Murphy, B. R. (1999). A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 17, 1100–1108.

Tao, T., Davoodi, F., Cho, C. J., Skiadopoulos, M. H., Durbin, A. P., Collins, P. L. & Murphy, B. R. (2000a). A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin–neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18, 1359–1366.

Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L. & Murphy, B. R. (2000b). Replacement of the ectodomains of the hemagglutinin–neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. Journal of Virology 74, 6448–6458.

Tapparel, C. & Roux, L. (1996). The efficiency of Sendai virus genome replication: the importance of the RNA primary sequence independent of terminal complementarity. Virology 225, 163–171.

Tapparel, C., Hausmann, S., Pelet, T., Curran, J., Kolakofsky, D. & Roux, L. (1997). Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins. Journal of Virology 71, 9588–9599.

Tapparel, C., Maurice, D. & Roux, L. (1998). The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)₃ is essential for replication. Journal of Virology 72, 3117–3128.

Techaarpornkul, S., Barretto, N. & Peeples, M. E. (2001). Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. Journal of Virology 75, 6825–6834.

Teng, M. N. & Collins, P. L. (1999). Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. Journal of Virology 73, 466–473.

Teng, M. N., Whitehead, S. S., Bermingham, A., St Claire, M., Elkins, W. R., Murphy, B. R. & Collins, P. L. (2000). Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. Journal of Virology 74, 9317–9321.

Teng, M. N., Whitehead, S. S. & Collins, P. L. (2001). Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289, 282–296.

Thomas, J. M., Stevens, M. P., Percy, N. & Barclay, W. S. (1998). Phosphorylation of the M2 protein of influenza A virus is not essential for virus viability. Virology 252, 54–64.

Tiley, L. S., Hagen, M., Matthews, J. T. & Krystal, M. (1994). Sequence-specific binding of the influenza virus RNA polymerase to sequences located at the 5´ ends of the viral RNAs. Journal of Virology 68, 5108–5116.

Tober, C., Seufert, M., Schneider, H., Billeter, M. A., Johnston, I. C., Niewiesk, S., ter Meulen, V. & Schneider-Schaulies, S. (1998). Expression of measles virus V protein is associated with pathogenicity and control of viral RNA synthesis. Journal of Virology 72, 8124–8132.

Valsamakis, A., Schneider, H., Auwaerter, P. G., Kaneshima, H., Billeter, M. A. & Griffin, D. E. (1998). Recombinant measles viruses with mutations in the C, V, or F gene have altered growth phenotypes in vivo. Journal of Virology 72, 7754–7761.

Volchkov, V. E., Becker, S., Volchkova, V. A., Ternovoj, V. A., Kotov, A. N., Netesov, S. V. & Klenk, H. D. (1995). GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214, 421–430.

Volchkov, V. E., Volchkova, V. A., Muhlberger, E., Kolesnikova, L. V., Weik, M., Dolnik, O. & Klenk, H. D. (2001). Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291, 1965–1969.

von Messling, V., Zimmer, G., Herrler, G., Haas, L. & Cattaneo, R. (2001). The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. Journal of Virology 75, 6418–6427.

Vulliemoz, D. & Roux, L. (2001). 'Rule of six': how does the Sendai virus RNA polymerase keep count? Journal of Virology 75, 4506–4518.

Wagner, E., Engelhardt, O. G., Gruber, S., Haller, O. & Kochs, G. (2001). Rescue of recombinant Thogoto virus from cloned cDNA. Journal of Virology 75, 9282–9286.

Walker, W. S., Castrucci, M. R., Sangster, M. Y., Carson, R. T. & Kawaoka, Y. (1997). HEL-Flu: an influenza virus containing the hen egg lysozyme epitope recognized by CD4⁺ T cells from mice transgenic for an / TCR. Journal of Immunology 159, 2563–2566.

Walsh, E. P., Baron, M. D., Anderson, J. & Barrett, T. (2000a). Development of a genetically marked recombinant rinderpest vaccine expressing green fluorescent protein. Journal of General Virology 81, 709–718.

Walsh, E. P., Baron, M. D., Rennie, L. F., Monaghan, P., Anderson, J. & Barrett, T. (2000b). Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope. Journal of Virology 74, 10165–10175.

Wang, X., Li, M., Zheng, H., Muster, T., Palese, P., Beg, A. A. & Garcia-Sastre, A. (2000). Influenza A virus NS1 protein prevents activation of NF-B and induction of / interferon. Journal of Virology 74, 11566–11573.

Watanabe, T., Watanabe, S., Ito, H., Kida, H. & Kawaoka, Y. (2001). Influenza a virus can undergo multiple cycles of replication without M2 ion channel activity. Journal of Virology 75, 5656–5662.

Watanabe, T., Watanabe, S., Neumann, G., Kida, H. & Kawaoka, Y. (2002). Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. Journal of Virology 76, 767–773.

Wertz, G. W., Whelan, S., LeGrone, A. & Ball, L. A. (1994). Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA. Proceedings of the National Academy of Sciences, USA 91, 8587–8591.

Wertz, G. W., Perepelitsa, V. P. & Ball, L. A. (1998). Gene arrangement attenuates expression and lethality of a nonsegmented strand RNA virus. Proceedings of the National Academy of Sciences, USA 95, 3501–3506.

Whelan, S. P. J. & Wertz, G. W. (1999). Regulation of RNA synthesis by the genomic termini of vesicular stomatitis virus: identification of distinct sequences essential for transcription but not replication. Journal of Virology 73, 297–306.

Whelan, S. P., Ball, L. A., Barr, J. N. & Wertz, G. T. (1995). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proceedings of the National Academy of Sciences, USA 92, 8388–8392.

Whelan, S. P., Barr, J. N. & Wertz, G. W. (2000). Identification of a minimal size requirement for termination of vesicular stomatitis virus mRNA: implications for the mechanism of transcription. Journal of Virology 74, 8268–8276.

Whitehead, S. S., Firestone, C. Y., Collins, P. L. & Murphy, B. R. (1998a). A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247, 232–239.

Whitehead, S. S., Juhasz, K., Firestone, C. Y., Collins, P. L. & Murphy, B. R. (1998b). Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. Journal of Virology 72, 4467–4471.

Whitehead, S. S., Bukreyev, A., Teng, M. N., Firestone, C. Y., St Claire, M., Elkins, W. R., Collins, P. L. & Murphy, B. R. (1999a). Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. Journal of Virology 73, 3438–3442.

Whitehead, S. S., Firestone, C. Y., Karron, R. A., Crowe, J. E., Jr, Elkins, W. R., Collins, P. L. & Murphy, B. R. (1999b). Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. Journal of Virology 73, 871–877.

Whitehead, S. S., Hill, M. G., Firestone, C. Y., St Claire, M., Elkins, W. R., Murphy, B. R. & Collins, P. L. (1999c). Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. Journal of Virology 73, 9773–9780.

Wright, P. F., Karron, R. A., Belshe, R. B., Thompson, J., Crowe, J. E., Jr, Boyce, T. G., Halburnt, L. L., Reed, G. W., Whitehead, S. S., Anderson, E. L., Wittek, A. E., Casey, R., Eichelberger, M., Thumar, B., Randolph, V. B., Udem, S. A., Chanock, R. M. & Murphy, B. R. (2000). Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Journal of Infectious Diseases 182, 1331–1342.

Yamanaka, K., Ogasawara, N., Yoshikawa, H., Ishihama, A. & Nagata, K. (1991). In vivo analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA. Proceedings of the National Academy of Sciences, USA 88, 5369–5373.

Yoshida, T., Shaw, M. W., Young, J. F. & Compans, R. W. (1981). Characterization of the RNA associated with influenza A cytoplasmic inclusions and the interaction of NS1 protein with RNA. Virology 110, 87–97.

Young, D. F., Didcock, L., Goodbourn, S. & Randall, R. E. (2000). Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 269, 383–390.

Young, D. F., Chatziandreou, N., He, B., Goodbourn, S., Lamb, R. A. & Randall, R. E. (2001). Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells. Journal of Virology 75, 3363–3370.

Yu, D., Shioda, T., Kato, A., Hasan, M. K., Sakai, Y. & Nagai, Y. (1997). Sendai virus-based expression of HIV-1 gp120: reinforcement by the V^– version. Genes to Cells 2, 457–466.

Yunus, A. S., Collins, P. L. & Samal, S. K. (1998). Sequence analysis of a functional polymerase (L) gene of bovine respiratory syncytial virus: determination of minimal trans-acting requirements for RNA replication. Journal of General Virology 79, 2231–2238.

Zhang, J., Leser, G. P., Pekosz, A. & Lamb, R. A. (2000). The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging. Virology 269, 325–334.

Zheng, H., Palese, P. & Garcia-Sastre, A. (1996). Nonconserved nucleotides at the 3´ and 5´ ends of an influenza A virus RNA play an important role in viral RNA replication. Virology 217, 242–251.

Zheng, H., Lee, H. A., Palese, P. & Garcia-Sastre, A. (1999). Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication. Journal of Virology 73, 5240–5243.

Zhou, Y., Konig, M., Hobom, G. & Neumeier, E. (1998). Membrane-anchored incorporation of a foreign protein in recombinant influenza virions. Virology 246, 83–94.

Zobel, A., Neumann, G. & Hobom, G. (1993). RNA polymerase I catalysed transcription of insert viral cDNA. Nucleic Acids Research 21, 3607–3614.

Zurcher, T., Luo, G. & Palese, P. (1994). Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formation. Journal of Virology 68, 5748–5754.

JGV Direct table of contents

© 2002 SGM